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Abstract 
Major Depressive Disorder (MDD) is a severe disease with almost 300 million people 
suffering worldwide (WHO 2019). By 2030, MDD is suggested to be identified as the global 
leading cause of disease burden. Only about 60% of patients react to a classical 
antidepressant (ADs) treatment and even if the subject is successfully treated and 
remission is achieved, the depressive disorder still imposes a considerable burden. 
Rarely, all of the symptoms disappear during remission and still depict an impairment to 
the patients’ daily life (Lépine and Briley 2011). The treatment of symptoms cannot be 
the sole ‘cure’ for MDD, rather a treatment of the cause is needed. Yet, the cause of MDD 
cannot be broken down to one single mechanism or factor, it is rather a variety of 
malfunctions leading to the manifestation of MDD. 
This study hypothesized the involvement of mitochondria and a bioenergetic imbalance 
for MDD patients. The mitochondrial respiration, the adenosine triphosphate (ATP) 
content, as well as the mitochondrial membrane potential (MMP) and the Ca2+ 
homeostasis were investigated in human cellular model. The mitochondria-related 
functions were assessed in somatic cells (human dermal fibroblasts) and neural 
progenitor cells (NPCs) derived from iPSCs of 16 MDD patients and 16 gender- and age-
matched healthy control subjects.  
Individuals with MDD showed significantly impaired mitochondrial functioning in 
fibroblasts under standard culturing conditions: basal and maximal respiration, spare 
respiratory capacity, non-mitochondrial respiration and ATP-related turnover is lower in 
Seahorse XFp Flux Analyzer respiratory measurements. Moreover, MDD fibroblasts 
harbor lower ATP levels determined by a bioluminescence assay. Measurements with the 
cationic dye JC-1 reveal a significantly more negative MMP in MDD fibroblasts, whereas 
the assessment of cytosolic Ca2+ with the ratiometric dye Fura-2 does not result in any 
significant differences. 
Additionally, fibroblasts were exposed to metabolic stress (galactose, 7 days) and 
hormonal stress (dexamethasone, 7 days). After the exposure to stress, the differences in 
bioenergetics in MDD fibroblasts were widely abolished and fibroblasts of both groups 
showed an overall significantly increased metabolism. 
In order to investigate the bioenergetics on a neuronal cellular level, the fibroblasts were 
episomally reprogrammed into iPSCs and differentiated into NPCs. Despite this process, 
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the mitochondria-related alterations discovered in MDD fibroblasts were also detectable 
in NPCs: A significantly lower basal and non-mitochondrial respiration and proton leak-
related oxygen consumption were discovered in respiratory measurements. Whereas 
ATP levels did not exhibit any significant differences, MDD NPCs showed a significantly 
more positive MMP and a trend towards altered Ca2+ homeostasis could be shown. Similar 
to the observations in fibroblasts, the differences between MDD patients and controls are 
not present after the exposure to hormonal stress (dexamethasone, 7 days).  
The results of the present study underpin the theory of a bioenergetic imbalance in MDD. 
It is likely that a mitochondrial dysfunction contributes to the pathophysiology of MDD 
and suggests that these alterations contribute to the biomolecular manifestation of 
depressive symptoms.  
Those differences in electron transport chain (ETC) function and the altered 
mitochondria-related properties depict a basis for further investigations of disease-
causing mechanisms. Furthermore, it might open new ways to gain insight into ADs-acting 
pathways, which could demonstrate a promising tool for new therapeutical approaches.  
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Zusammenfassung 
Die Unipolare Depression, mit weltweit mehr als 300 Millionen Betroffenen, ist eine 
schwerwiegende Krankheit (WHO 2019). Es wird prognostiziert, dass die Unipolare 
Depression bis zum Jahr 2030 die weltweit führende Krankheitsbelastung darstellt. Auf 
eine Behandlung mit klassischen Antidepressiva sprechen nur in etwa 60% der Patienten 
an und selbst wenn eine Remission erreicht wird, erlegt die Depression den Betroffen 
noch immer eine Last auf.  Selten sind die Patienten während der Remission symptomfrei 
und leiden unter den damit einhergehenden täglichen Einschränkungen (Lépine und 
Briley 2001).  Die alleinige Behandlung der Symptome kann nicht die ,,Heilung‘‘ der 
Depression sein - vielmehr wird eine Behandlung der Ursache benötigt. Der Grund für die 
Entstehung einer Depression kann jedoch nicht an einem einzigen Mechanismus oder 
Faktor festgemacht werden. Es ist eher eine Vielzahl an Fehlfunktionen, welche 
schlussendlich zur Manifestation einer Depression führen. 
Im Zuge dieser Studie wird eine Beteiligung der Mitochondrien als einer dieser Faktoren 
vermutet und es wird angenommen, dass ein bioenergetisches Ungleichgewicht in 
depressiven Patienten vorliegt. In einem humanen Zellmodell werden die mitochondriale 
Respiration, der Gehalt an Adenosin-Triphosphat (ATP), wie auch das mitochondriale 
Membranpotential (MMP) und der Ca2+-Haushalt untersucht. Diese mit Mitochondrien 
assoziierten Funktionen werden in somatischen Zellen (humanen dermalen 
Fibroblasten)  und neuralen Vorläuferzellen von 16 depressiven Patienten und 16 alters- 
und geschlechtsangepassten gesunden Kontrollen betrachtet.  
Die Fibroblasten von Personen mit einer Unipolaren Depression zeigen signifikant 
eingeschränkte mitochondriale Funktionen unter Standard-Kulturbedingungen: Basale 
und  maximale Respiration, respiratorische Reservekapazität, nicht-mitochondriale 
Respiration und die ATP-produktionsabhängige Atmung sind verringert in Seahorse XFp 
Flux Analyzer Messungen. Außerdem besitzen Fibroblasten von Patienten einen 
niedrigeren ATP Gehalt, welcher mit Hilfe eines Biolumineszenz Assays bestimmt wurde. 
Messungen mit dem kationischen Farbstoff JC-1 resultieren in einem signifikant 
negativeren MMP in Patientenfibroblasten, wohingegen keine signifikanten Unterschiede 
in den Messungen des zytosolischen Ca2+ mittels des ratiometrischen Farbstoffes Fura-2 
festgestellt werden können. 
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Zudem wurden die Fibroblasten eine Woche lang metabolischem Stress in Form von 
Galaktose und hormonellem Stress durch die Zugabe des synthetischen Glukokortikoids 
Dexamethason ausgesetzt. Durch die Anwendung dieser Stressprotokolle wurden die 
bioenergetischen Unterschiede in den Patientenfibroblasten weitestgehend aufgehoben 
und Patienten- als auch Kontrollfibroblasten zeigen generell eine gesteigerte 
metabolische Aktivität.  
Um die Bioenergetik auf einem neuralen Zelllevel zu untersuchen, wurden die 
Fibroblasten zu induzierten pluripotenten Stammzellen reprogrammiert und zu neuralen 
Vorläuferzellen differenziert. Trotz dieses Prozesses können die Veränderungen in der 
Mitochondrienfunktion, welche vor der Reprogrammierung in den Patientenfibroblasten 
gemessen wurden,  auch in den neuralen Vorläuferzellen nachgewiesen werden: Eine 
signifikant verringerte basale und nicht-mitochondriale Atmung wurden in 
Respirationsexperimenten ermittelt. Obgleich der ATP-Gehalt der neuralen 
Vorläuferzellen sich zwischen Patienten und Kontrollen nicht unterscheidet, konnte ein 
signifikant verringertes MMP und ein Trend zu einer veränderten Ca2+-Homöostase 
gezeigt werden. Ähnlich den Beobachtungen in Fibroblasten, sind die Unterschiede in 
Patienten und Kontrollen auch bei neuralen Vorläuferzellen nach hormonellem Stress 
(Dexamethason, 7 Tage) nicht mehr vorhanden. 
Die Ergebnisse dieser Studie untermauern die Theorie eines bioenergetischen 
Ungleichgewichts bei einer Unipolaren Depression. Es ist sehr wahrscheinlich, dass eine 
mitochondriale Dysfunktion zur Pathophysiologie der Unipolaren Depression beiträgt 
und es gibt Hinweise, dass diese Veränderungen einen Einfluss auf die biomolekulare 
Manifestation der depressiven Symptome haben. 
Die veränderte Funktion der Elektronentransportkette und die abweichenden 
Eigenschaften bezüglich der Mitochondrien legen einen Grundstein für weitere 
Untersuchungen von Mechanismen, welche Depressionen verursachen. Des Weiteren 
könnten diese Entdeckungen neue Wege und Möglichkeiten bieten, einen Einblick in 
Wirkmechanismen von Antidepressiva zu gewinnen, welche wiederum eine 
vielversprechende neue Methode darstellen neue therapeutische Ansätze zu eröffnen. 
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1 Introduction 
1.1 Mitochondria – the vital force in our cells 
1.1.1 Mitochondria structure and the site of action 
The human body harbors trillions of mitochondria. For a eukaryotic cell’s function 
mitochondria are vital. Hundreds to thousands of small bacteria-sized (0.5-1 µM) 
mitochondria ensure the cell’s energy supply. The number of mitochondria varies among 
cell type, tissue and organ, depending on the energetic needs. Muscle and cardiac cells, 
neurons and liver cells, for instance, contain up to 2,000 mitochondria, whereas red blood 
cells do not have them at all. However, mitochondria do not only vary in number, but also 
in size and shape. Mitochondria have – among many others – one key function: the 
provision of the cell with energy in form of ATP, which is pivotal for the maintenance of 
the cell’s proper function and survival. To fulfill this crucial task, mitochondria have a 
special structure: They are double-membraned, with an outer (OMM) and an inner 
membrane (IMM), an intermembrane space (IMS), cristae and the matrix (Alberts et al. 
2002).  
 
 
Figure 1 The organization of the mitochondrion. The outer membrane encloses the inner membrane possessing 
cristae, where the ETC machinery is located. The matrix of the mitochondrion contains granules, ribosomes and 
the mtDNA. 
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The mitochondrion is enclosed by OMM that is equipped with porins for the exchange of 
metabolites. Between the OMM and the IMM is the IMS. The smooth OMM, consisting of a 
lipid-double layer, has numerous embedded proteins. Large integral proteins called 
porins form the connection between the cell’s cytosol and the IMS. Those porins are the 
major junction to the cells‘ surrounding and they are responsible for the transport of 
nucleotides, ions and metabolites (Alberts et al. 2002). One of these important gateways 
from outside to the IMS of mitochondria is the voltage-gated anion channel (VDAC) that 
extends over the OMM. VDAC is described as a large aqueous pathway from a single 
30 kDa protein; a channel, that does not only have the purpose of the exchange of small 
hydrophilic molecules across the OMM. VDAC displays multi-faceted features and is able 
to form complexes with proteins and enzymes and responds to the protein concentration 
of the cytoplasm (Colombini 2004). Hence, VDAC, in association with the Translocator 
Protein 18 kDa (TSPO), for example, depicts a noteworthy equipment of the OMM setup 
and therefore the entire mitochondrial structure (Shoshan-Barmatz, Pittala, and Mizrachi 
2019). 
Enzymes and proteins also run through the IMM. The TOM complex in the OMM and the 
TIM complex situated in the IMM are multimeric protein assemblies which enable protein 
transport across the double membrane. Most importantly, the proteins of the ETC are 
embedded into the IMM. To extend the membrane and enlarge its surface, the IMM has 
cristae. The cristae are foldings of the IMM and just like the number, size and shape of the 
mitochondria itself, they differ widely along cell types. Muscle cells and neurons, for 
instance – cells types hat require a high energetic demand - show large cristae in order to 
gain some extra space for the machinery of oxidative phosphorylation (OXPHOS): the 
process which creates chemical energy (Alberts et al. 2002). 
The matrix contains the mitochondrial DNA (mtDNA). The mtDNA is a small, circular and 
multi-copy genome. It includes 37 mitochondrial genes whereof 13 mt genes are coding 
for essential components of the mitochondrial ETC and the ATP synthase. Each 
mitochondrion can contain 2–10 copies of mtDNA (Robin and Wong 1988). 
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Figure 2 The ETC and the mechanism of OXPHOS in mitochondria. Through the transfer of electrons at the 
Complexes I-IV of the respiratory chain the reduction equivalents and the pumping of protons from the mitochondrial 
matrix the mitochondrial membrane potential is built up. This electrochemical gradient drives the ATP synthase that 
converts ADP and inorganic phosphate the cell’s most valuable energy carrier ATP. 
 
 
The respiratory chain is the ‘’site of action’’ and through OXPHOS the final products of the 
tricarboxylic acid (TCA) cycle and glycolysis are metabolized. Via OXPHOS basically the 
metabolism of sugars is completed and the mitochondrion fulfills its major function in the 
cell: the energy supply in form of ATP.  In the respiratory chain, the reduction equivalents 
NADH and FADH2 derived from the TCA cycle are oxidized through serial redox reactions. 
Besides H2O and CO2, 36 molecules of ATP are synthesized. The respiratory chain is built 
up of four protein complexes and the ATP synthase located at the IMM. At Complex I 
(NADH Ubiquinone-Oxidoreductase) two electrons are transferred from NADH/H+ to 
ubiquinone. Two further electrons are transferred from FADH2 to ubiquinone at Complex 
II, called the Succinate-Ubiquinone-Oxidoreductase. At the third Complex (Ubiquinone-
Cytochrome-c-Oxidoreductase) two molecules of Cytochrome c (Cyt c) are reduced by the 
transfer of two electrons from ubiquinol. Finally, at Complex IV (Cyt c-Oxidase), Cyt c is 
reoxidized under the reduction of O2 to H2O. Besides the transport of electrons along the 
reduction equivalents, protons are pumped from the matrix of the mitochondrion into the 
IMS. Therefore, an electrochemical gradient is built up over the IMM. This proton motive 
force drives the ATP synthase and enables the generation of ATP from ADP+Pi (Alberts et 
al. 2002).  
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Figure 3 The ATP synthase. The ATP synthase is located at the IMM and consists of two subunits, which are in 
turn built up of several subunits. The hydrophobic F0 (consisting of a, b, c) is situated in the membrane and forms 
a proton channel: it converts the flux of the protons through the membrane into a rotation, with whose help the ATP 
synthase is driven. The hydrophilic F1-subunit (put together by the alpha, beta, gamma, delta and epsilon unit), 
sticks out of the IMM into the matrix, where from ADP und Pi ATP are synthesized. The OSCP-subunit also belongs 
to the F1-complex and plays an important role when it comes to stabilization of the F1-subunit against the rotation 
of the F0-subunit. 
 
 
1.1.2 Mitochondria in the cellular metabolism 
The mitochondrion’s key function, the OXPHOS, cannot be seen as a separate mechanism, 
independently passing off in the mitochondrion. Mitochondria are involved in a network 
of metabolic pathways and the products of these important metabolic pathways are 
transformed into energy and eventually, mitochondria are the organelles keeping the cell 
alive. Metabolites from lipid degradation, glycolysis and the TCA cycle convert in the 
mitochondrion.  
Oxidative metabolism of both glucose and free fatty acids result in the generation of the 
key metabolite Acetyl-CoA. During the oxidation of one molecule glucose into two 
molecules pyruvate, net 2 ATP and 2 NADH are generated. Pyruvate is converted by 
enzyme complex pyruvate dehydrogenase into two molecules of Acetyl-CoA, which is 
trafficked from the cytosol into the mitochondrion. During β-oxidation fatty acids are 
broken down in a four-step reaction: The β-carbon is oxidized to ketone followed by the 
cleavage of the α- and the β-carbon which yields after all one molecule Acetyl-CoA and the 
reduction equivalents NADH and FADH2. In the TCA cycle, Acetyl-CoA is oxidized in an 
eight steps process in the mitochondrial matrix outside the cristae. Each molecule of 
Acetyl-CoA yields 3 molecules of NADH and one molecule of FADH2. These reduced 
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nucleotide coenzymes subsequently transfer electrons to molecular oxygen via the ETC 
and ATP is generated from ADP and inorganic phosphate (Alberts et al. 2002). 
Mitochondria are the main source of endogenously produced reactive oxygen species 
(ROS). ROS are a byproduct of OXPHOS which is produced by the ETC through the 
reduction of O2 to superoxide. In order to prevent oxidative stress by overwhelming 
amounts of ROS, cells harbor an antioxidative defense (Roma et al. 2017). The 
mitochondrial enzymes superoxide dismutase (SOD) and thioredoxin-2 (TRX2) scavenge 
free radicals and strive for an equilibrium in the cell. Another endogenous antioxidant 
system with mitochondrial involvement is the glutathione (GSH) peroxidase system 
(Tanaka et al. 2002).  
 
 
Figure 4 Mitochondria in the cellular metabolism. Mitochondria are involved in crucial cellular functions including 
biosynthesis as well as degradation of metabolites, bioenergetics and energy supply and balance and signaling of 
ROS. The key processes – glycolysis, β-oxidation of fatty acids, the TCA cycle and one-carbon metabolism – in the 
cell and in the mitochondrion and their interplay are depicted.  
 
 
However, ROS is necessary for the cell and its production is imperative for redox 
homeostasis. Balanced ROS levels are vital for the cell‘s homeostasis. ROS signalling is not 
only part of the immune system, but it also mediates cell proliferation and apoptotic 
pathways to ensure proper regulation of the cell cycle and programmed cell death (Roma 
et al. 2017). Ca2+ homeostasis is the second key player in cell survival and apoptosis. Ca2+ 
as second messenger molecule mediates intracellular signalling cascades as well as cell-
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cell-signalling (Clapham 2007). Mitochondria regulate cytosolic Ca2+ levels and 
consequently Ca2+-mediated signalling. Mitochondrial Ca2+ levels are crucial for the rate 
of OXPHOS.  Uncoupling proteins 1, 2 and 3 (UCP1, UCP2, UCP3) are embedded in the IMM  
and belong to the superfamily of mitochondrial ion transporters (Ricquier and Bouillaud 
2000) . UCP1 accounts for heat production by inducing a H+ leak that uncouples OXPHOS, 
whereas UCP2 and UCP3 contribute to many cellular processes including mitochondrial 
free-radical production, apoptosis, hormone secretion and they are implicated in glucose 
and fatty acid metabolism (Dejean et al. 2004; Harper et al. 2002; Krauss et al. 2003; 
Mookerjee et al. 2010). Most importantly, UCP2 and UCP3 were shown to be fundamental 
for mitochondrial Ca2+ transport (Graier, Trenker, and Malli 2014).  
Besides those transport systems, Ca2+ signalling and buffering is accomplished by 
interfaces of the mitochondria and the endoplasmic reticulum (ER) and are entitled 
mitochondria-associated ER membranes (MAMs). Proteins in MAM either are involved in 
physical connection between ER and mitochondria or modify the tethering complexes in 
MAMs. Mitofusin 1/2 (Mfn1/2), a mitochondrial fusion GTPase, which situated to the 
OMM, is part of the MAM complex. MFN1/2 plays a role in mitochondrial fusion and 
together with OPA1, another mitochondrial fusion GTPase, which located at the IMM, 
regulates the merging of mitochondria  (De Brito and Scorrano 2008; Cipolat et al. 2004; 
Detmer and Chan 2007). 
 
 
1.1.3 Fission and fusion: a dynamic network 
Mitochondria are highly dynamic organelles and change their shapes and distribution 
constantly. Mitochondria’s shapes range from small vehicles, short rods and reticular 
networks spanning the entire cell. Their rapid changes in shape and location, allow 
mitochondria a fast adaption to energetic needs and they are essential to mitochondrial 
health, wherefore damaged organelles or precipitates are restored and removed. 
Mitochondrial fission and fusion events are balanced and have been identified as a critical 
process in mitochondrial morphology and function. As mentioned beforehand, and most 
importantly, fission and fusion control the shape length and number of mitochondria. 
Additionally, the shape of mitochondria affects the ability of cells to distribute their 
mitochondria to specific subcellular locations. By continuous merger and division, the 
exchange of lipid membranes and intra-mitochondrial content is ensured (Charmandari, 
Tsigos, and Chrousos 2005; Gold et al. 2002; Kyrou, Chrousos, and Tsigos 2006; Detmer 
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and Chan 2007). Defects in fission and fusion come with severe diseases. Dysregulation of 
those two processes are associated with an energetic defect, giving the hint that 
mitochondrial structure and function are tightly related (Bertholet et al. 2016; Lee and 
Yoon 2016). Mfn1 and Mfn2 are responsible for OMM fusion, whereas OPA1 regulates the 
fusion of the IMM. Fission events in mammals are mediated by the dynamin-like protein 
1 (drp1), which is predominantly a cytosolic protein (Meeusen et al. 2006; Yonashiro et 
al. 2009). Fibroblasts that lack both, Mfn1 and Mfn2, show reduced respiratory capacity 
and individual mitochondria show great heterogeneity in shape and membrane potential. 
Cells that lack OPA1 show similar defects, with an even greater reduction in respiratory 
capacity (Chen, Chomyn, and Chan 2005).  
 
 
 
 
Figure 5 Fission and Fusion events. (a) Wild-type cells with intact mitochondrial dynamics. Functioning 
mitochondria are shown in green, whereas mitochondria with defects and lack of mtDNA are shown in orange. By 
fusion events the deficiencies in non-functional mitochondria can regain its function and mtDNA by fusing with a 
neighbouring mitochondrion. The fused mitochondrion then undergoes fission, with both daughter mitochondria 
receiving mtDNA nucleoids. (b) Cells with fusion-deficient properties. The mitochondria are fragmented since fission 
events are still happening. Cells lack mtDNA nucleoids accumulate because there is no pathway for defective 
mitochondria to regain mtDNA. Fusion-deficient cells can maintain mtDNA nucleoids, but such nucleoids serve a 
much smaller mitochondrial mass. 
 
 
Hence, mitochondrial dynamics are extremely important for mitochondrial function. 
Mitochondria should not be seen as separate organelles but as a population of organelles 
with heterogeneous functions. Information and contents are being exchanged and 
deficient mitochondria can be rescued by others. A few mitochondria might be non-
functional owing to the loss of essential components. However, this dysfunction is 
transient, since mitochondrial fusion provides a pathway for these defective 
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mitochondria to regain essential components (figure 5). An essential prerequisite for 
proper mitochondrial function is mitochondrial DNA (mtDNA) which is organized in 
nucleoids. The mtDNA genome encodes important subunits of the respiratory Complexes 
I, III and IV, and is therefore indispensable for OXPHOS. When mitochondrial fusion is 
abolished, a large fraction of the mitochondrial population loses mtDNA nucleoids (Chen, 
McCaffery, and Chan 2007). When mitochondria divide, most daughter cells inherit at 
least one mtDNA nucleoid. If this inheritance fails, fusion events compensate for that and 
the mtDNA is restored in the daughter cell. Since in cells with disturbed mitochondrial 
dynamics, the exchange of contents does not take place, the restoration of mtDNA 
nucleoids probably accounts for the heterogeneity in mitochondrial MMP and the reduced 
respiratory capacity. Cells with a lack of fusion capability, however, still harbour a 
significant number of mtDNA nucleoids. Due to fission events, the functional 
mitochondrial mass gets reduced. Furthermore, not only the mtDNA gets restored by 
mitochondrial fusion, but also other components like substrates, metabolites and specific 
lipids can be recovered in disturbed mitochondria (Detmer and Chan 2007). Concluding, 
the mitochondrial mass is strongly influenced by mitochondrial dynamics and might 
reflect the cell’s health or disease state. The cellular mtDNA content is regulated by the 
nuclear DNA that encodes for in mtDNA replication, transcription, translation and repair. 
Molecular defects in the genes responsible for mtDNA biogenesis and therefore a 
reduction of mtDNA content. It is known that mtDNA depletion and a lack of the 
maintenance of mtDNA integrity can lead to a series of disorders. Those diseases include, 
for instance, Leigh-like encephalopathy with dystonia, deafness and lactic acidosis 
combined with encephalomyopathy, but also mitochondrial hepatoencephalopathy with 
hepatic and neurologic symptoms during infancy (Dimmock et al. 2008; Ostergaard et al. 
2007; Sarzi et al. 2007; Wong et al. 2008). 
Studies also reported alterations of the mitochondrial mass in mood disorders. MtDNA 
copy number is reduced in leucocytes of Schizophrenia (SZ) and Bipolar Disorder (BPD) 
patients and could be correlated to the severity of disease and the anti-psychotic 
treatment. They suggested a link between mitochondrial dysfunction and psychosis-like 
symptoms (Kumar et al. 2018). Decreased number of mtDNA in leucocytes was revealed 
for MDD (Kim et al. 2013). Decreased mtDNA copy numbers were also discovered with 
increasing duration of the Posttraumatic Stress Disorder (PTSD) symptoms, whereas the 
copy number is highest in the initial phase of PTSD (Bersani et al. 2016). Moreover, for 
patients with MDD, anxiety disorder or adjustment-disorder an increased mtDNA copy 
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numbers in peripheral blood is reported and it is positively correlated to the severity of 
disease (Karabatsiakis et al. 2014). It might be assumed that higher mtDNA copy numbers 
compensate for dysfunctional mitochondrial metabolism and the resulting energetic 
deficiencies (Wang et al. 2017).  
 
 
1.2 Major Depressive Disorder – a multifactorial disease 
1.2.1 Classification and diagnostics  
Sadness, emptiness, hopelessness, a loss of interest and pleasure – MDD has many faces. 
The severe disease is of high heterogeneity and multifaceted in the clinical picture. 
Symptoms include changes in mood, cognition, interest, but also troubles in decision-
making, anxiety, anhedonia, problems in volition and motivation and changes with 
respect to psycho-motility and energy. Furthermore, appetite and therefore weight and 
the circadian rhythm can be affected. According to Diagnostic and Statistical Manual of 
Mental Disorders V (DSM V) classification two out of three main symptoms - a depressed 
mood, anhedonia and the lack of drive and some of the side symptoms, respectively 
somatic symptoms include troubles in cognition, reduced self-esteem, feelings of guilt 
and/or hopelessness, changes in appetite, sleep disturbances and the expression of 
meaninglessness of life – so suicidal ideation – must be present for at least 2 weeks nearly 
every day. MDD is diagnosed based on physician-administered or patient self-
administered interview and is still subjective since it depends on the individual clinical 
judgment (Bilello 2016; Young et al. 2016). MDD state is evaluated through a 
questionnaire that determines the severity of depression. The Hamilton Depression Scale 
(HAM-D) ranges from 0 (no depression) to 10-20 scores (mild depression) to 21-30 
scores (medium severe depression). More than 30 points are considered as a severe MDD. 
Classification according to ICD-10 Classification of Mental and Behavioral Disorders. 
Clinical Descriptions and Diagnostic guidelines (ICD-10) provides the following categories: 
 
- F32.0: Mild depressive episode: Two or three of the symptoms are present. The 
subject is generally impaired and is seeking for help, however he/she is still able 
to fulfill occupational and private routine.  
- F32.1: Medium severe depressed episode: Usually four or more of the symptoms 
are present. The subject has severe troubles continuing daily routine. 
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- F32.2: Severe depressed episode without psychotic symptoms: Several of the 
symptoms are present to a torturous extent. Subjects typically exhibit a loss of self-
esteem and worthlessness and affected persons utter suicidal thoughts and 
actions. Persons additionally suffer from somatic symptoms, e.g. agitation, sleep 
disturbances or loss of appetite or libido. 
- F32.3: Severe depressed episode with psychotic symptoms: State of disease is 
described as F32.2, but additionally subjects suffer from hallucinations and 
delusional ideas, psychomotor inhibitions or stupor, so that daily social activities 
are impossible and persons are in danger of life due to suicide and a lack of 
imbibition and ingestion. 
- 32.8: Other depressive episode. 
- 32.9: Depressed episode, not specified. 
 
 
Figure 6 Symptoms of MDD and its increasing impact on daily performance. A combination of symptoms concerning 
emotional status, vegetative and cognitive function must be present over a period of 2 weeks. Increasing number 
of a combination of manifestations causes cumulative functional impairment. Main symptoms for depression are 
marked with a red dot. The color green indicates emotional symptoms, blue color stands for neurovegetative 
symptoms and orange depicts neurocognitive symptoms.  
 
 
MDD has a severe impact on the affected persons. It is a disease with tremendous societal, 
economic and emotional burden and results in an impairment in social or occupational 
functioning and therefore impairs daily living (Kessler and Bromet 2013). MDD is 
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considered as a global burden with 1 to 17% of affected people in adults, 3 to 6% in 
adolescents, and 12 to 38% in elderly (Gururajan et al. 2016; Kessler and Bromet 2013; 
Rantamaki and Yalcin 2016). MDD is one of the leading causes of mental disability 
worldwide, with an estimated lifetime prevalence of up to 20–30% (Weissman et al. 
1996). Moreover, women are affected more frequently than men (Kessler and Bromet 
2013). MDD is highly comorbid with somatic diseases like diabetes, asthma and arthritis, 
but also with neurodegenerative disorders like Alzheimer’s disease (AD), Parkinson’s 
diseases (PD) and Huntington’s disease (HD) (Kupfer, Frank, and Phillips 2012; Réus et 
al. 2016). 
MDD is a multifactorial disease including, genetic and epigenetic factors, the exposure to 
stress or traumatic events and the interaction with other psychological or environmental 
factors and even personality itself plays a role in the manifestation of MDD (Rantamaki 
and Yalcin 2016; Schneider and Prvulovic 2013). It is assumed, that for MDD patients 
neuronal circuits are affected and neuronal connectivity is altered, leading to functional 
neuroanatomical modifications (Rantamaki and Yalcin 2016). From a molecular point of 
view, neurobiological, but also neuroendocrine, neurotrophins as well as oxidative stress 
and inflammatory processes contribute to the manifestation of MDD and several theories 
for the development of the disease merged the last decades. 
 
 
1.2.2 Early and new theories for manifestation  
The oldest hypothesis that is postulated with regard to the manifestation of MDD is the 
monoaminergic theory of depression. It claims that the underlying pathophysiologic basis 
for the manifestation of MDD is a lack of monoamines like serotonin, norepinephrine 
and/or dopamine in the synaptic cleft. Tricyclic antidepressants (TCAs) and selective 
serotonin reuptake inhibitors (SSRIs) are the most common treatments for the MDD 
(Bartl et al. 2014; Eisenhofer, Kopin, and Goldstein 2004). These medications elevate the 
level of neurotransmitters in the brain by either prolonging their presence in the synaptic 
cleft or blocking their presynaptic auto-receptors. Depressive symptoms are effectively 
reversed by monoamine oxidase inhibitors (MAOIs) and TCAs, however with a delayed 
onset. Drugs acting on the monoaminergic system usually need at least 2 to 8 weeks 
before a therapeutic effect can be observed and each drug is only efficient in around two 
third of MDD patients (Sonnenberg et al. 2008). Besides that, the observed discrepancy 
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between pharmacological and biochemical function of ADs and their clinical mood 
altering responses  remains unclear (Leonard 2007).  
Therefore, additional neurotransmitter systems came into play and newer theories 
postulate that monoamine deficiency cannot be the sole underlying reason for the 
development of depression. The neuroplasticity theory of depression includes other 
transmitters like Glutamate and γ–butyric acid (GABA), but also the Brain-Derived-
Neurotrophic factor (BDNF). The glutamatergic system may be also implicated in MDD 
(Hashimoto 2009). Fast-acting drugs like Ketamine, which is an antagonist of the NMDA-
receptor, revealed antidepressant effects (Dutta, McKie, and Deakin 2015). Moreover, it is 
likely that the glutamatergic system is involved in the manifestation of MDD, since 
increased glucocorticoid levels, which are released under conditions of chronic stress that 
associated with depression, lead to enhanced glutamatergic transmission, elevated NMDA 
receptor expression and increased extracellular glutamate levels (Lu et al. 2003). 
Glutamate and GABA are both involved in synaptic plasticity and various studies 
implicated GABA in the pathophysiology of depression (Krystal, Sanacora, and Duman 
2013; Luscher, Shen, and Sahir 2011). 
Synaptic plasticity is an important process in the brain including synaptogenesis, 
alterations in dendritic function, neurite extension, synaptic remodelling and 
modification of synaptic neurotransmissions. ADs treatment can – at least partly - reverse 
this disturbed plasticity which contributes to a pathological state (Pittenger and Duman 
2008; Wood et al. 2004). The modulation of receptors for serotonin and noradrenaline 
through ADs treatment, different downstream pathways get activated that have a 
common function which is the regulation of gene expression, e.g. BDNF, which is crucial 
for the formation of neuronal networks (Yu and Chen 2011). 
Numerous studies also suggest that inflammation may contribute to symptoms relevant 
to a number of psychiatric disorders and particularly depression. Inflammation and 
depression are linked and there is strong evidence that one goads the other, in the sense 
that inflammatory responses can lead to depression and depression can lead to 
inflammation. It is known that patients with inflammatory diseases are more likely to 
show greater rates of MDD. Moreover, patients with high inflammation have been shown 
to react poorly to conventional ADs therapies (Felger 2018). A large number of people 
with MDD show elevated peripheral inflammatory biomarkers, even in the absence of a 
medical illness. Several studies have reported increased circulating inflammatory 
cytokines, such as interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF), their soluble 
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receptors, and acute phase reactants, like C-reactive protein (CRP), in patients with MDD 
(Maes 1999; Maes et al. 1992; Sluzewska 1999). And coming back to neurogenesis and 
alterations in brain signaling pattern, inflammatory mediators have been found to alter 
glutamate and monoamine neurotransmission as well as glucocorticoid receptor (GR) 
resistance (Amodeo, Allegra Trusso, and Fagiolini 2018). 
A dysfunction of GRs, elevated levels of glucocorticoid hormones and the accompanied 
disturbed feedback mechanism of the hypothalamus-pituitary-adrenal (HPA) axis is 
strongly associated with MDD (Vreeburg et al. 2009). ADs act on the upregulation of the 
HPA axis and moderate the hyperactivity by ameliorating many of the neurobiological 
disturbances in depression and relief depressive symptoms (Anacker et al. 2001).  
 
 
1.3 The risk factor stress - impact on mitochondria and mood 
1.3.1 The stress response in the human body 
The human stress response is a homeostatic mechanism that provides a better chance of 
survival when the body is under threat. It mobilizes neural and hormonal networks to 
optimize cognitive, cardiovascular, immunological and metabolic function. 
The HPA axis is the key pathway in the human stress response and reacts immediately to 
a real or perceived stressor. It is the central mediator of the ‘’fight or flight’’ reaction.  
 
 
Figure 7 The Hypothalamic-Pituitary-Adrenal Axis. An internal or external stressor induced the releases of CRH 
from the hypothalamus which causes a release of ACTH from the pituitary gland. ACTH acts on the adrenal glands 
and elevated levels of Cortisol follows. Cortisol action is regulated by a negative feedback mechanism on the 
hypothalamus. Source: https://images.agoramedia.com/everydayhealth/gcms/What-Is-Cortisol-722x406.jpg 
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The HPA axis is a complex combination of organs and transmitters with a feedback 
mechanism. Internal, e.g. the circadian rhythm, and external signals, like stress, trigger 
the hypothalamic release of corticotropin releasing hormone (CRH), which acts on the 
anterior pituitary, which in turn stimulates the synthesis and secretion of 
adrenocorticotropic hormone (ACTH) in the pituitary gland. ACTH then acts on the 
adrenal cortex to stimulate the production and secretion of Cortisol, a glucocorticoid (GC). 
The GCs that are released, mediate through GRs which are expressed throughout the 
entire body and trigger negative feedback mechanism by also targeting the hypothalamus 
and anterior pituitary. The production and release of CRH and ACTH are inhibited and 
thereby limit both, the intensity and duration, of the GC increase (Oakley and Cidlowski 
2013). Hence, the stress response is crucial for our homeostasis and survival and comes 
along with beneficial adaptations on a cellular and molecular level. 
 
1.3.2 Benefits of acute stress 
Not just the release of CRH, ACTH and GCs are typical for the stress response, but also the 
release of catecholamines, adrenaline and noradrenaline, as well as pro-inflammatory 
factors TNF-α, IL-1 and IL-6. Altogether, the secreted substances ensure the fast response 
that includes effective blood supply in the brain, the cardiac muscle and the skeletal 
muscle. Furthermore, the energy production is enhanced by recruiting substrates like 
glucose, fatty acids and amino acids from storages. Besides that, the optimal ATP 
availability to vital tissues is orchestrated (Charmandari, Tsigos, and Chrousos 2005). 
Mitochondria are the pivotal organelle when it comes to biosynthetic activities and the 
supply of energy. Together with their involvement in Ca2+ metabolism, signaling, the 
regulation of thermogenesis and the generation of ROS, as well as the decision makers 
over cell survival or apoptosis, they are the first organelles to react to stressors 
(Klinedinst and Regenold 2014). Oxygen consumption and total energy expenditure are 
increased during the initial phase of the acute stress. Several signalling pathways are 
activated to meet energy demands during stress situations. Firstly, a higher number of 
mitochondria are recruited and they increase their volume. The expression and the 
activity of OXPHOS units are enhanced and the uncoupling of the respiratory chain and 
consequently energy in the form of heat is released. Besides that, the ROS level is 
regulated which is in turn important for signalling and defence and finally, an apoptotic 
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cascade is triggered, depending on the nature of the stressor (Goldenthal and Marin-
Garcia 2004).  
Mitochondrial function is affected and enhanced through GR action. GRs are expressed in 
mitochondria in several cell types (Demonacos et al. 1995). There is evidence that short-
term exposure to stress and the concentration of GCs is associated with induction of 
mitochondrial biogenesis and enzymatic activity of the ETC units. For instance, by acute 
exposure of skeletal muscles to the synthetic GC dexamethasone, the transcription 
primarily of nuclear genes, but also mtDNA-encoded genes, affecting mitochondrial 
function and biogenesis, are initiated (Mikes et al. 2002). Mitochondrial biogenesis and 
OXPHOS and consequently adaptive thermogenesis in adipose tissue as well as in the 
skeletal muscle are stimulated by the catecholamines that are released. In brown adipose 
tissue energy saved from OXPHOS of substrates is dissipated as heat instead of the storage 
in form of ATP: this process is denominated as ‘uncoupling’. The process of uncoupling is 
beneficial for the cell, as it attenuates mitochondrial ROS production and protects against 
cellular damage (Brand and Esteves 2005). Another signalling pathway that is activated 
during acute stress is the peroxisome proliferator-activated receptor-coactivator 1-α 
(PGC-1α) signalling pathway. Cytokines, such as TNF-a, IL-1, which are immediately 
released, trigger the transcriptional activity of PGC 1-α via direct phosphorylation and 
activation the mitogen-activated protein kinase (MAPK) pathway. This results in 
stabilization and activation of PGC-1α protein, which is the master regulator of 
mitochondrial biogenesis. PGC 1-α switches on gene expression that drives mitochondrial 
biogenesis and OXPHOS, again directing the metabolism towards mitochondrial 
uncoupling and energy expenditure (Michael et al. 2001; Wu et al. 2006). 
Taken together, the acute effects of stress on the human body and the downstream effects 
are beneficial and necessary for the reaction to a stressor in general. But what happens 
when the perceived or actual stressor is persistent and the human body is steadily 
exposed to stress? 
 
1.3.3 Sustained stress and its deleterious consequences 
Chronic exposure to stress results in reversal of the beneficial effects. The long-term 
cortisol exposure becomes maladaptive, which can lead to a broad range of problems 
including the metabolic syndrome, obesity, cancer, mental health disorders, 
cardiovascular disease and increased susceptibility to infections (Björntorp and Rosmond 
2000; Pufall 2015a; Steckler, Holsboer, and Reul 1999; Strüber, Strüber, and Roth 2014a). 
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However, starting with the initial process leading to these serious diseases: the activation 
of the HPA axis and the release of GCs, adrenaline and cytokines. Prolonged exposure to 
GCs causes respiratory chain dysfunction, increased ROS generation, mitochondrial 
structural abnormalities, apoptosis and cell death. Even if the release of GC is crucial and 
necessary in a stressed state, an overload of cortisol – regardless if naturally secreted or 
synthetic GCs administered through pharmacological treatments – is associated with 
various serious diseases (Charmandari, Tsigos, and Chrousos 2005; Chrousos 2000; Gold 
et al. 2002; Kyrou, Chrousos, and Tsigos 2006). The beneficial PCG1-α signalling, which is 
necessary for mitochondrial biogenesis, can become maladaptive and is detrimental to 
the cell in response to persistent stressors. PGC-1α overexpression for instance, caused 
hepatic insulin resistance, manifested by higher glucose production and diminished 
insulin suppression of gluconeogenesis (Liang et al. 2009). Another study was able to 
show, also in a murine model, that the overexpression of PGC1-α leads to cardiomyopathy 
(Russell et al. 2004).  Abnormally increased mitochondrial biogenesis leads to an elevated 
level of ROS. Increased oxidative damage in form of elevated levels of stress markers and 
genetic modification, namely telomere shortening, was revealed in children of mother 
with chronical psychological stress (Epel et al. 2004). In this context, especially the NF-κβ 
pathway is highly sensitive to changes in the intracellular redox environment and thus 
can be activated by oxidative stress. Mitochondrial gene expression can be negatively 
regulated in response to cellular TNF-α stimulation (Cogswell et al. 2003). Moreover, 
exceeded TNF-α release induces apoptosis in several cell types. TNF-α mediated 
apoptosis requires binding of the cytokine to its receptor TNFR1. This triggers a 
downstream activation of caspase 8 increasing Cyt c release which is followed by a loss of 
the MMP and the induction of apoptosis (Micheau and Tschopp 2003). Moreover, mtDNA 
is sensitive to oxidative damage. Mutations in the mtDNA can lead to altered transcription 
and expression of the ETC enzymes, which causes pathologic changes of mitochondrial 
function (Shokolenko et al. 2009). 
It is known that chronic stress alters ingestion behavior. Nutrient overload and a 
carbohydrate- and lipid-rich diet leads to an excess of GC and is associated with abdominal 
obesity. It is very likely that overweight is accompanied by the development of diseases 
affecting metabolism, e.g. metabolic syndrome, type-2 diabetes and cardiovascular 
disease (Krempler et al. 2002; Patti et al. 2003). Disruptions of the OXPHOS and mtDNA 
abnormalities cause changes in PGC 1-α expression and UCP2. PGC 1- α and UCP2 play a 
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crucial role in proton leak and thermogenesis and they are linked diabetes and the 
metabolic syndrome (Brand and Esteves 2005).  
 
 
 
 
Figure 8 Mitochondrial functions in the stress response. This figure summarizes important mitochondrial functions 
including (a) the energy production through OXPHOS, (b) the generation of ROS and (c) the induction of apoptosis 
by opening of the mitochondrial permeability transition pore (mtPTP). By the release of Cyt c and the activation of 
Apaf1, the Apoptosome is triggered downstream and caspase activation follows. Alongside, the mitochondrion’s 
most important signaling pathways are shown. (d) By adrenergic receptor activation, cAMP and PKA are activated. 
By cytokine receptor activation, the p38 MAPK pathway is triggered, which in results an activation of the major 
upstream regulator of mitochondrial function-related gene expression, the PGC-1α. Exposure to stressors, such as 
cold temperature, fasting, exercise, cachexia or chronic infection activates PGC-1α. (e) The release of GC during 
the stress response nuclear and mitochondrial genes regulating mitochondrial biogenesis and function are activated 
and the GRs can enter the mitochondrion and regulate mtDNA transcription. (f) A ‘mitochondria-specific stress 
response’ takes place by a retrograde signalling from the mitochondrion to the nucleus.  
 
 
Elevated diurnal GC levels are a characteristic for depressed subjects and they remain 
high even after remission from a depressed episode (Beluche et al. 2009; Belvederi Murri 
et al. 2014). A constant state of stress in form of high cortisol levels constitutes one 
important neurobiological characteristic of depression (Stetler and Miller 2011). Chronic 
stress, which is defined as stress ongoing for more than 12 months, is a stronger predictor 
of depressive symptoms than acute stressors (Hammen 2005). There is clear evidence, 
that the severity and number of negative, stressful events increases the probability for an 
onset of a depressed phase (Kendler, Karkowski, and Prescott 1998). Resuming the facts 
of persisting stress, the long-term elevation of cortisol and its molecular downstream 
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effects as one of the biggest risk factors for the manifestation of MDD, a fundamental role 
of dysfunctional mitochondria and their pathogenic impact is reasonable. 
 
 
1.4 Mitochondria and disease – what we know so far 
1.4.1 Mitochondriopathies 
Primary and secondary mitochondriopathies are described as clinical, biochemical and 
genetic diseases. The disorders are caused either by mutations of the maternally inherited 
mitochondrial genome or nuclear DNA mutations. The clinical manifestation of a 
mitochondriopathy is in the first place not dependent on the localisation of the mutation 
or the cell type, organ or the affected person, but rather on the distribution across cell 
types and the extent of the mtDNA mutations. Besides the genetic variation of the mtDNA 
itself, epigenetic factors contribute to the clinical picture (Finsterer 2004). 
Mitochondriopathies can be distinguished according to different aspects. Firstly, primary 
and secondary mitochondriopathies are differentiated. Primary mitochondriopathies 
include mutations in the mtDNA or the nDNA, or in both. A secondary mitochondriopathy 
is defined by a normal mitochondrial DNA, however the mitochondria are structurally 
modified. Secondary mitochondriopathies prevail along muscle dystrophies, glycogenosis 
or myositis. The biochemical defect is another aspect. Myopathies can be considered and 
categorized according to the molecular changes: defects in the respiratory enzymes, 
respectively substrate transporters or protein shuttles, alterations in the β-oxidation or 
pyruvate oxidation or the citrate cycle (Morgan-Hughes 1996). Alternatively, it can be 
distinguished among the clinical symptoms. Those symptoms are of high variety and 
range from muscle dystrophies, ophtalmoplegia and vision loss, to metabolic diseases like 
diabetes. Epilepsy and physical or mental retardation are typical for 
mitochondriophathies, too (Walker and Collins 1996). Clinically classified mitochondrial 
symptoms are for example Chronic Progressive External Opthalmoplegia (CPEO), Kearns 
Sayre Syndrom (KSS), Mitochondrial Encephalomyopathy- Lactic Acidosis and Stroke-like 
Episodes (MELAS), myoclonic epilepsy and ragged red fibres (MERRF) or maternally 
inherited Leigh Syndrome (MILS). It is known, that people primarily diagnosed with a 
mitochondriopathy, show comorbidities with psychiatric disorders. A high comorbidity 
of mitochondrial MELAS in SZ and bipolar affective disorder has also been documented 
(Oexle and Zwirner 1997; Prayson and Wang 1998; Siciliano et al. 2003). Moreover, an 
acute confused state and SZ-like hallucination syndrome are sometimes observed in 
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patients with MELAS. Cases of mitochondrial encephalopathies presenting MDD or BPD 
have also been reported (Kato and Kato 2000). 
 
1.4.2 Mitochondrial disruption in neurodegenerative diseases 
Mitochondrial dysfunction and abnormalities have been reported in several neurological 
disorders. Typical neurodegenerative disorder with mitochondrial involvement are 
Alzheimer’s disease (AD), Parkison’s disease (PD), Amyotrophic Lateral Sclerosis (ALS) 
or Huntington’s disease (HD). The most common cause for these illnesses is mitochondrial 
ageing and as a consequence thereof, an accumulation of mtDNA mutations and the net 
production of ROS. Throughout lifespan, increasing number of large scale deletions and 
point mutations are acquired (Corral-Debrinski et al. 1992). Several IS proteins including 
Cyt c, second mitochondrial activator of caspases (SMAC) and high-temperature 
requirement protein A2 (HTRA2) have pro-apoptotic functions when released to the 
cytoplasm. An accumulation of deletions and point mutations in genes that are 
responsible for apoptosis, are considered to contribute to a diminished mitochondrial 
function and survival. Defects in ROS scavenging enzymes like mitochondrial superoxide 
dismutase (MnSOD) or methionine sulfoxide reductase A (MSRA) are related to a 
shortened mitochondrial life span. Oxidative damage notably contributes to AD-related 
pathology. For instance, deficiencies in the MnSOD enzyme activity was shown to increase 
amyloid-β-peptide (Aβ) levels, which is the primary component of senile plaques 
(Velliquette, O’Connor, and Vassar 2005). Moreover, amyloid precursor protein (APP), 
which gives rise to Aβ, was detected to interact with the ER and mitochondria directly. An 
exceed of APP blocks the mitochondrial protein import machinery and causes 
mitochondrial dysfunction and impaired energy metabolism (Anandatheerthavarada et 
al. 2003). 
A characteristic for PD is neuronal loss in the substrantia nigra pars compacta (SN). 
Surviving nigral neurons may contain intracytoplasmic inclusions called Lewy bodies. The 
presence of Lewy bodies in the SN constitutes the histologic diagnosis. Lewy bodies 
consist largely of fibrillar α-synuclein and its aggregation is promoted by Complex I 
inhibition in cell culture and PD animal models. The functional disruption and the 
elevation of oxidative stress on PD are induced by mutations in further nuclear encoded 
genes like phosphatase and tensin homologue (PTEN)-induced kinase 1 (PINK1), leucine-
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rich-repeat kinase 2 (LRRK2) which directly or indirectly involve biogenetic metabolism 
and mitophagy (Swerdlow 2009).  
For ALS, progressive weakness, muscle atrophy, spasticity, and eventual paralysis are 
typical. The neurological disruptions origin from a degeneration of upper and lower 
motor neurons. Frequent mutations detected in ALS include changes in genes encoding 
for SOD1, which protects for oxidative damage and which is implicated in apoptosis. SOD1 
is considered to be a cytoplasmic enzyme, but it is also identified to be membrane-
associated in mitochondria. Mutations in SOD1 in mice exhibit altered mitochondrial 
morphology and SOD1 accumulation, which underpins that mutant SOD1 drives 
neurodegeneration by damaging mitochondria (Gurney et al. 1994; Wong et al. 1995). 
Moreover, Complex I, II and III activities have been reported to be increased in vulnerable 
and non-vulnerable regions of patients with SOD1 mutations, whereas Complex IV activity 
was decreased in the spinal cord and skeletal muscle.   
Abnormalities in mitochondrial morphology in skeletal muscles, liver and spinal cord 
motor neurons were detected in ALS patients (Borthwick et al. 2001; Comi et al. 1998). 
Moreover, Ca2+ homeostasis is altered in mitochondria of skeletal muscles of ALS patents. 
Despite of an increased number of local mitochondrial in synaptic terminals of motor 
neurons, Ca2+-mediated processes in mitochondria appear to be disrupted (Siklós et al. 
1996). In familial ALS patients Cyt c activity was reduced, indicating changes in proper 
mitochondrial metabolism and cellular survival (Comi et al. 1998). 
HD is defined by a mutation of the Huntingtin gene on chromosome 4 and characterized 
as a hyperkinetic movement disorder. Various metabolism-related enzymes including the 
ETC complexes are altered in HD. The contribution of Huntingtin in particular remains 
unclear. However, Huntingtin was shown to be associated with the mitochondrial 
membrane and therefore it is likely to be involved in Ca2+ handling. Furthermore, 
Huntingtin is reported to disrupt PGC-1α and thereby affecting mitochondrial metabolism 
(Swerdlow 2009). 
 
1.4.3 Dysfunction of mitochondria and psychiatric disorders 
Several brain disorders including MELAS, Leigh Syndrome, Friedrich’s Ataxia as well the 
aforementioned neurodegenerative diseases AD, PD, ALS and HD result from mtDNA 
mutations. It is suggested that a malfunction of ROS production and disturbed 
mitochondrial metabolism contribute to the manifestation. Other studies also implicate 
the effect of oxidative stress on the development of mood disorders (Barton et al. 2003; 
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Forlenza and Miller 2006; Ozcan et al. 2004). Psychiatric symptoms also occur in subjects 
with mitochondriopathies. Several cases were documented that report of mitochondrial 
disorders with a comorbidity of psychiatric diseases including BPD, MDD, psychosis, 
anxiety disorders, and personality changes. Depressive episodes are reported with CPEO, 
whereas MELAS is highly correlated with SZ and BPD (DiMauro and Moraes 1993; Oexle 
and Zwirner 1997; Prayson and Wang 1998; Siciliano et al. 2003). Hence, brain 
metabolism seems to be disrupted which is caused by mtDNA mutation. These mutations 
causing mitochondrial abnormalities induce a patho-psychological state. Vice versa, in 
subjects primarily diagnosed with mental illnesses, especially MDD, bioenergetic deficits 
can be detected. 
 
 
1.5 From fibroblasts via induced pluripotent stem cells through to induced 
neurons - a cellular model for MDD 
In order to study mitochondrial metabolism in psychiatric disorders, a suitable model is 
needed. Whereas postmortem studies of brains can provide information about genetic 
variations, protein expression, changes in brain structures and volume alterations of 
different regions as well as the network of brain cells, several factors may interfere with 
tissue and molecular preservation of these samples and induce changes in the post-
mortem state of the brain compared to pre-mortem (Ferrer et al. 2008). Therefore, 
functional and enzymatic studies are preferably conducted in intact, living cells from MDD 
subjects. Moreover, mitochondria constantly undergo fusion and fission, form networks 
and crosstalk with other subcellular compartments (Picard et al. 2011). This emphasizes 
also the need to analyze mitochondrial function without, or at least with minimal, cell 
disruption and with an as close as possible physiological environment, declining 
observations with isolated mitochondria or even frozen or fixed tissue. Nevertheless, 
brain studies in patients with MDD revealed that cellular bioenergetics are imbalanced 
and are related to mitochondrial dysfunction (Iosifescu et al. 2008; Stork and Renshaw 
2005; Videbech 2000). Recent investigations in intact peripheral cells present 
bioenergetic changes in peripheral blood mononuclear cells (PBMCs), muscle cells, 
platelets and fibroblasts in correlation with a MDD state. Gardner et al. discovered a 
decreased ATP production and enzyme ratios comprising Complex I+III/Complex IV and 
the Complex II+III/Complex IV ratios in mitochondria of muscle cells in MDD patients 
(Gardner et al. 2003). Another study revealed that MDD patients lacking any ADs 
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treatment or pharmacological interventions exhibited significantly increased nitric oxide 
levels and a heightened MMP in platelets compared with those observed in control 
subjects (Moreno et al. 2013). Hroudová et al. also investigated platelets and were able to 
unveil reductions in mitochondrial physiological respiration, maximal capacity of the ETC 
and a lower respiratory rate after Complex I inhibition (Hroudová et al. 2013). Human 
fibroblasts of MDD patients show on a mRNA and miRNA level changes induced by 
metabolic stress. Those alterations indicate MDD-associated impairments in molecular 
pathways which are involved in guiding metabolism and energy production, cell survival, 
proliferation and migration (Garbett et al. 2015).  
Moreover, patients with MDD had significantly lower basal and maximal respiratory 
rates in PBMCs than controls (Karabatsiakis et al. 2014).  
 
Lorenz et al. investigated the mitochondrial metabolism and defects in the mtDNA not in 
somatic cells as the aforementioned studies, but in iPSCs derived from human fibroblasts, 
NPCs and induced neurons (iN). They were able to show that despite the process of 
reprogramming, the parental mtDNA profile is retained. Moreover, they revealed that 
cells from iPSCs via NPCs through to iN exhibit a metabolic switch towards OXPHOS. The 
differentiated NPCs from patients carrying a deleterious homo-plasmic mutation mtDNA 
mutation showed defective ATP production and abnormal MMP besides an altered Ca2+ 
homeostasis, which might display a potential cause of neural impairment. The results of 
the study of Lorenz et al. highlighted that iPSC-derived NPCs provide an effective model 
for the investigation of bioenergetic changes, not only due to genetic changes that take 
place during development, but also that the cell types itself throughout neural 
development are a suitable model (Lorenz et al. 2017). Another study also emphasizes the 
importance of NPC investigation and their metabolic switch from aerobic glycolysis to 
OXPHOS, on which neurons rely on for their energy provision. They demonstrated the 
importance of this developmental changes since this process is critical for neural 
development. Defects during neuronal development cause neurological as well as 
neurodegenerative diseases (Zheng et al. 2016). 
Klein Gunnewiek et al. elucidated mitochondrial dysfunction by the means of iPSC stem 
cell technology. They generated and observed excitatory cortical neurons with normal 
and impaired mitochondrial function due to the common pathogenic m.3243A>G 
mutation causing MELAS. iN with high levels of mtDNA mutations showed mitochondrial 
dysfunction, delayed neural maturation, receded dendritic complexity and less functional 
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synapses with a reduced network activity. These structural changes and failed proper 
integrity of iN are suggested to be a result of impaired metabolism in neurons bearing 
pathogenic mutation. These observations are proposed to enhance the susceptibility to 
neuropsychiatric manifestation because of a mitochondrial disease (Klein Gunnewiek et 
al. 2019). 
A study highlighted iPSC-derived neurons as a model to investigate mental disorders – 
BPD in the particular case – and its potential for developing new therapies and drugs 
aiming for clinical treatment. iN of BPD patients exhibited mitochondrial abnormalities 
and a hyperexcitability which could be reversed by lithium treatment in neurons derived 
from patients who also responded to lithium (Mertens et al. 2015).  
Various studies proved iPSCs, NPCs and iN as models for the investigation of metabolic 
changes, as well as an appropriate in vitro system to examine potential mitochondrial 
defects and bioenergetic alterations throughout development in disease. The iPSC 
technology from somatic cells to neural cell types is a suitable way to approach the 
implication of mitochondria in MDD in the present study. 
 
 
1.6 Bioenergetic imbalance in MDD – hypothesis and aim of the thesis 
In the present study, we focus on the association of mitochondria function and MDD. 
Potential pathomechanisms related to mitochondrial dysfunction and the bioenergetics 
imbalance in cells from MDD patients compared to healthy subjects should be elucidated. 
Based on the recent findings by Garbett et al., Hroudová et al., Karabatsiakis et al. and 
others, we hypothesize that mitochondria function is altered in somatic cells of MDD 
patients, as well as in neural cells.  
In a first approach, the bioenergetic core function, the function of the ETC and OXPHOS, is 
examined in human dermal fibroblasts by the Seahorse XFp Flux Analyzer. It enables the 
assessment of the respiratory flux by the direct measurement of the oxygen consumption 
rate (OCR), which can be seen as a measure of the efficiency of the ETC. In the presence of 
the naturally available substrates, the OCR can be correlated to the function of the 
different respiratory complexes. The application of chemical compounds interfering with 
the ETC reveals the activity and capacity. Besides that, the aim is to investigate the overall 
energetic state in both, MDD fibroblasts and fibroblasts from controls. Measurements 
 
39 Introduction 
with the Seahorse XFp Flux Analyzer allow the assessment of the proton secretion, the 
extracellular acidification rate (ECAR), which is a measure for glycolysis. 
In addition, the energetic capacity in form of ATP is investigated by the direct 
measurement of the ATP content using a bioluminescence-based assay in order to unravel 
differences in MDD fibroblasts and control fibroblasts.  
The ETC builds up an electro-chemical gradient between the IMS and the mitochondrial 
matrix, which is degraded by the ATP synthase and uncoupling proteins. This MMP over 
the IMM serves as an indicator for the bioenergetic state of mitochondria and might give 
a hint at a bioenergetic imbalance resulting from mitochondrial malfunction. Therefore, 
an objective is the assessment of the MMP in live cell imaging experiments with the help 
of the cationic dye JC-1. 
Another objective of this thesis is to observe the homeostatic function of mitochondria 
and to elucidate potential differences in MDD cells and cells from healthy subjects. 
Mitochondria in association with the ER possess a Ca2+ -buffer function, which is closely 
related to the negative MMP. Alterations in the MMP might result in higher or lower 
cytosolic Ca2+ levels and consequently changes in cellular Ca2+-mediated signaling. 
Peripheral, non-neuronal cells are suitable for the investigation of mitochondrial 
functions and their implication in psychiatric disorders – like this case for MDD disease 
modeling. Nevertheless, in the focus of interest of this thesis is also to investigate whether 
potential alterations in the mitochondrial function in fibroblasts are also detectable in 
precursor-like state of neurons, the neural progenitor cells (NPCs). Reprogrammed 
somatic cells and cells that undergo the differentiation process experience changes in 
their energetic demands. Therefore, the cell’s metabolism adapts and metabolism 
switches from efficient OXPHOS to fast but less efficient glycolysis and back to OXPHOS. 
NPCs are an intermediate state between iPSCs and iNeurons, and as this developing cell 
stage is pivotal to neuronal growth and differentiation, the research focus of this thesis is 
the mitochondrial (dys)function and bioenergetic (im)balance in MDD NPCs. This study 
hypothesizes, that also neural cells from MDD patients harbor alterations in their 
mitochondrial function. Therefore, the goal is to reprogram fibroblasts into iPSCs 
(Takahashi and Yamanaka 2006) and differentiate those into NPCs by the application of 
different growth factors and to control for proper neural induction by 
immunocytochemical staining (Yan et al. 2013). Similar to the focus of research in somatic 
cells, an important objective is to conduct the respiratory experiments with the Seahorse 
XFp Flux Analyzer in NPCs derived from MDD patients and compare their properties to 
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those from NPCs from healthy controls. Moreover, another objective is to determine the 
ATP levels in NPCs by a bioluminescence assay.  
Likewise in fibroblasts, it is hypothesized that possible changes in the respiration also 
cause differences in the MMP in NPCs and go along with alterations in their Ca2+ 
homeostasis. In order to investigate this issue, live cell imaging experiments are 
conducted with NPCs. The cationic dye JC-1 is used to assess the MMP and cytosolic Ca2+ 
levels are determined with the ratiometric dye Fura-2. 
Furthermore, the impact of hormonal stress in form of Dexamethasone (1 µM, 7d) and 
metabolic stress induced by the replacement of glucose by galactose (10 mM, 7d) on 
mitochondria function and metabolism is a main objective. 
Whether the differences in the bioenergetics, which might be unveiled in the previously 
described approaches, are actually due to an ETC malfunction or simply by a reduced 
mitochondrial mass, the mitochondrial DNA copy number is determined in patient and 
control cells. 
This study aims for a better insight into mechanisms related to the manifestation of MDD 
and seeks for shedding light on the indispensable proper function of a small but crucial 
organelle – the mitochondrion – assuring not only a healthy body, but also a healthy mind. 
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2 Materials 
2.1 Lab supplies 
Table 1 Lab supplies used in the present study 
Material Manufacturer 
6-well-/12-well-/24-well-plate Corning Incorporated; Tewksbury, Massachusetts 
Agilent Seahorse XFp Flux Cartridge Agilent Technologies; Santa Clara, California 
Agilent Seahorse XFp Flux Miniplate Agilent Technologies; Santa Clara, California 
cell strainer 100 µm Greiner Bio One; Kremsmünster, Austria 
chamber for coverslip (ø 25 mm) Warner Instruments; Hamden, Conneticut 
coverslips, glass (ø 25 mm, ø 12 mm) Menzel Gläser; Braunschweig, Germany 
cryo Vials 2mL Lab Solute by Th. Geyer; Renningen, Germany 
Eppendorf cups (0. 5mL- 5 mL) Eppendorf; Hamburg, Germany 
Erlenmeyer flask 250 mL Corning Incorporated; Tewksbury, Massachusetts 
Falcon tubes (15 mL, 50 mL) Corning Incorporated; Tewksbury, Massachusetts 
mircoplates 96-well (black bottom) Greiner Bio One; Kremsmünster, Austria 
mircoplates 96-well (transparent) Greiner Bio One; Kremsmünster, Austria 
parafilm PECHINEY Plastic Packaging; Chicago, Illinois 
Pasteur pipette Carl Roth; Karlsruhe, Germany 
petridish (ø10 cm) Sarstedt; Nümbrecht, Germany 
pipette 0.1-10 µL Eppendorf; Hamburg, Germany 
pipette 10 µL - 200 µL Eppendorf; Hamburg, Germany 
pipette 100 µL - 1000 µL Eppendorf; Hamburg, Germany 
pipette filter tips Sarstedt; Nümbrecht, Germany 
pipette tips (10 µL, 200 µL, 1200 µL) Sarstedt; Nümbrecht, Germany 
pipettor Brand GmbH&Co. KG; Wertheim, Germany 
stripette, glass (5 mL) Corning Incorporated; Tewksbury, Massachusetts 
stripettes, plastic (1 mL, 5 mL, 10 mL, 25 mL)  Corning Incorporated; Tewksbury, Massachusetts 
T75 flask Sarstedt; Nümbrecht, Germany 
 
 
2.2 Reagencies, chemicals and kits 
Table 2 Chemicals required for the experiments of the study 
Reagency Manufacturer 
0.5 M EDTA pH 8.0 Invitrogen by Life Technologies; Carlsbad, 
California 
Accutase Gibco by Life Technologies; Carlsbad, California 
Advanced DMEM Gibco by Life Technologies; Carlsbad, California 
Agilent Seahorse XF Base Medium Agilent Technologies; Santa Clara, California 
Antibiotic/Antimycotic solution Sigma-Aldrich; St. Louis, Missouri 
Antimycin A Cayman Chemical Company; Ann Arbor, Michigan 
CASYton buffer OMNI Life Science; Bremen, Germany 
dexamethasone Cayman Chemical Company; Ann Arbor, Michigan 
dextrose Carl Roth; Karlsruhe, Germany 
ethanol 100% Merck; Darmstadt, Germany 
Dispase STEMCELL Technologies; Vancouver, Canada 
DMEM Gibco by Life Technologies; Carlsbad, California 
DMEM/F12 Gibco by Life Technologies; Carlsbad, California 
DMSO Sigma-Aldrich; St. Louis, Missouri 
DPBS Gibco by Life Technologies; Carlsbad, California 
E7 Medium STEMCELL Technologies; Vancouver, Canada 
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FCCP Cayman Chemical Company; Ann Arbor, Michigan 
FCS Sigma-Aldrich; St. Louis, Missouri 
FCS dialyzed PAN Biotech; Aidenbach, Germany 
Fluorescent Mounting Medium Dako; Carpinteria, California 
Fura-2/AM (‘’Fura-2’’) Gibco by Life Technologies; Carlsbad, California 
galactose Carl Roth; Karlsruhe, Germany 
gentamycin Gibco by Life Technologies; Carlsbad, California 
JC-1 Invitrogen by Life Technologies; Carlsbad, 
California 
L-Glutamine Sigma-Aldrich; St. Louis, Missouri 
matrigel Corning Incorporated; Tewksbury, Massachusetts 
mTeSR STEMCELL Technologies; Vancouver, Canada 
mTeSR Supplement 50X STEMCELL Technologies; Vancouver, Canada 
NaOH Carl Roth; Karlsruhe, Germany 
Neural Induction Supplement Gibco by Life Technologies; Carlsbad, California 
Neurobasal Medium Gibco by Life Technologies; Carlsbad, California 
non-essential amino acids Gibco by Life Technologies; Carlsbad, California 
normal goat serum Thermo Fisher Scientific; Carlsbad, California 
Oligomycin Cayman Chemical Company; Ann Arbor, Michigan 
OptiMEM Gibco by Life Technologies; Carlsbad, California 
paraformaldehyde Carl Roth; Karlsruhe, Germany 
DPBS Gibco by Life Technologies; Carlsbad, California 
Penicilin-Streptomycin Sigma-Aldrich; St. Louis, Missouri 
Pluronic 10% F127 Thermo Fisher Scientific; Carlsbad, California 
Rotenone Cayman Chemical Company; Ann Arbor, Michigan 
sodium butyrate Sigma-Aldrich; St. Louis, Missouri 
sodium pyruvate Gibco by Life Technologies; Carlsbad, California 
RNase free water MACHERY-NAGEL; Düren, Germany 
CryoStore CS10 BioLifeSolutions; Bothell, Washington 
STEMdiff Neural Progenitor Freezing 
Medium 
STEMCELL Technologies; Vancouver, Canada 
Triton X-100 Sigma-Aldrich; St. Louis, Missouri 
Trypan Blue Sigma-Aldrich; St. Louis, Missouri 
Trypsin Sigma-Aldrich; St. Louis, Missouri 
Vitronectin XF STEMCELL Technologies; Vancouver, Canada 
 
 
Table 3 Kits 
Kit Manufacturer 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific; Carlsbad, California 
CellTiter Glo Cell Viability Assay Promega; Madison, Wosconsin  
Seahorse XFp Mito Stress Kit Agilent Technologies; Santa Clara, California 
Human Dermal Fibroblast Nucleofector Kit 
VPD-1001 
Lonza; Basel, Switzerland 
QIAmp DNA Mini Kit Qiagen; Hilden, Germany 
Takyon Amplification Technologies Eurogene; Seraing, Belgium 
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2.4 Antibodies 
Table 4 Antibodies for Immunocytohemistry 
Antibody (AB) Dilution Type of  AB Manufacturer 
Hoechst 1:1000 primary Gibco by Life 
Technologies; Carlsbad, 
California 
Anti-PAX6 (mouse) 1:10 primary PAX6 was deposited to 
the DSHB by Kawakami, A. 
(DSHB Hybridoma 
Product PAX6) 
Anti-SOX2 ab97959 
(rabbit) 
1:1000 primary Abcam; Cambridge, UK 
Anti-mouse Cy3 1:1000 secondary Thermo Fisher Scientific; 
Carlsbad, California 
Anti-rat 488 1:1000 secondary Gibco by Life 
Technologies; Carlsbad, 
California 
 
2.5 Culture media and buffer compositions 
Table 5 Primary Fibroblast Medium 
Component Volume 
DMEM 500 mL 
FCS 50 mL 
Antibiotic/Antimycotic Solution 5 mL 
 
 
Table 6 Primary fibroblast freezing medium 
Component Volume 
Primary Fibroblast Medium 35 mL 
FCS 10 mL 
DMSO 5 mL 
 
 
Table 7 E7 Medium 
Component Volume 
TeSR-E7 480 mL 
TeSR-E7 25X Supplement 20 mL 
 
 
Table 8 mTeSR Medium 
Component Volume 
mTeSR Basal Medium 400 mL 
mTeSR Supplement 50X 100 mL 
Gentamycin (2000X) 250 µL 
 
 
Table 9 Neural Induction Medium 
Component Volume 
Neurobasal Medium 49 mL 
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Neural Induction Supplement 1 mL 
 
Table 10 Neural Expansion Medium 
Component Volume 
Neurobasal Medium 24.5 mL 
Advanced DMEM/F12 Medium 24.5 mL 
Neural Induction Supplement 1 mL 
Penicillin/Streptomycin 250 µL 
 
 
Table 11 Blocking buffer 
Component Volume 
0.5% Triton-X100 1 mL 
10% normal goat serum 1 mL 
1X PBS 1 mL 
ddH2O 7 mL 
 
 
Table 12 Antibody buffer 
Component Volume 
0.5% Triton-X100 200 µL 
10% normal goat serum 200 µL 
1X PBS 1 mL 
dd H2O 8.6 mL 
 
 
Table 13 Seahorse Assay Medium pH=7.4 
Component Volume 
XFp Base Assay Medium 24 mL 
1 M glucose 500 µL 
sodium pyruvate 100 mM 250 µL 
L-Glutamine 200 mM 250 µL 
 
 
Table 14 Ringer’s solution, pH=7.4 
Component Volume 
NaCl 140 mM 46.7 mL 
KCl 5 mM 1 mL 
MgCl2 2 mM 2 mL 
HEPES 10 mM 50 mL 
ddH2O 900.3 mL 
 
 
Table 15 Phosphate Buffered Saline pH=7.3 
Component Concentration 
NaCl 137 mM 
KCl 2.7 mM 
Na2HPO4 8 mM 
KH2PO4 1.4 mM 
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3 Methods 
3.1 Study participants 
Primary fibroblast lines were obtained by skin biopsy conducted by Dr. Leopold Größer, 
Dr. Konstantin Drexler and Prof. Dr. Mark Berneburg, Department of Dermatology, 
University Hospital of Regensburg, Regensburg, Germany. All 16 patients are diagnosed 
with MDD (Unipolar Depression, Hamilton Score > 18, diagnosed according to ICD-10) 
and responded to ADs medication. For the 16 gender- and age-matched healthy control 
subjects no current psychiatric disorder was recorded (Hamilton score 0-3). 
 
 
Table 16 Study participants and controls 
Patient 
 
Gender Age Hamilton 
Score 
Control 
 
Gender Age Hamilton 
Score 
MDD1 M 48 24 CON1 M 49 3 
MDD2 F 49 21 CON2 F 50 0 
MDD3 M 19 24 CON3 M 25 0 
MDD4 M 48 20 CON4 M 45 1 
MDD5 M 19 23 CON5 M 24 0 
MDD6 F 24 23 CON6 F 25 1 
MDD7 F 44 22 CON7 F 49 0 
MDD8 F 44 22 CON8 F 53 0 
MDD9 M 21 22 CON9 M 21 0 
MDD10 M 21 21 CON10 M 20 1 
MDD11 M 23 31 CON11 M 24 1 
MDD12 F 23 34 CON12 F 23 0 
MDD13 M 23 32 CON13 M 23 0 
MDD14 M 30 28 CON14 M 27 0 
MDD15 M 31 28 CON15 M 30 0 
MDD16 M 34 25 CON16 M 35 0 
 
 
Biopsy material of healthy skin (ø 4 mm) is cut into 6 to 10 smaller pieces, put into 6 wells 
of a 6-well-plate, attached for 5-7 minutes and covered with Primary Fibroblast Medium 
(PrimFibM), consisting of DMEM/F12 supplemented with 10% fetal calf serum and 1% 
Antibiotic/Antimycotic solution (Anti/Anti). The primary fibroblasts determined passage 
0 are cultured for 2-3 weeks until wells reach a confluence of 80-90%, then they are split 
(see 3.2) and transferred into T75 flasks for further growth. 
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3.2 Adult human dermal fibroblasts  
3.2.1 Culturing conditions 
Fibroblast cell lines are cultured at 37 °C and 5% CO2 in PrimFibM in either 6-well-plates 
for experimental purposes or T75 flasks/ø10 cm petri dishes for further culturing. Cell 
cultures are checked daily under Olympus IX70 inverted cell culture transmitted-light 
microscope (Olympus Corporation; Tokyo, Japan). The medium is changed every other day. 
 
3.2.2 Passaging, freezing and thawing procedure 
When the cells reach around 80- 90% of confluence, they are prepared for splitting. The 
medium is aspirated and the cells are incubated with pre-warmed 1 mM PBS/EDTA for 
15 min at 37°C in order to facilitate detachment. Subsequently, they are enzymatically 
detached by adding pre-warmed Trypsin for 5 min at 37 °C. By adding culture media, the 
reaction is stopped and the cell suspension is transferred into a 15 mL Falcon tube. After 
centrifugation for 5 min at 800 rpm, the cell pellet is resuspended properly in culture 
media and 200 µL are transferred into an Eppendorf cup for counting. 
Cell counting was done with the CASY Cell Counter (OMNI Life Science; Bremen, Germany; 
see 3.2.3). 
The volume with the desired amount of cells is seeded onto 6-well-plates or in a T75 
flask/ø10 cm petri dish.  
 
 
Table 17 Volumes for fibroblast splitting procedure 
 1 well/6-well-plate T75 flask/ 
ø10 cm petri dish 
1 mM PBS/EDTA 1 mL 5 mL 
Trypsin 0.5 mL 2 mL 
PrimFibM (stopping reaction) 1.5 mL 8 mL 
PrimFibM (resuspending) 2 mL 6-10 mL 
 
 
For freezing, the cells are split as described above, apart from resuspending the cell pellet. 
After aspiration of the medium, the cell pellet is taken up in 1 mL of fibroblast freezing 
medium and transferred into a 1.5 mL cryo store vial. An evenly freezing of the sample is 
guaranteed by putting the vials into an isopropanol container. The cells are stored for 
short-term purposes at -80 °C and long-term at -196 °C. 
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For thawing, the fibroblasts in cryo vials are put shortly into the waterbath (37 °C) and 
afterwards, they are transferred into a 15 mL Falcon tube with 5-10 mL of PrimFibM. The 
suspension is centrifuged for 5 min at 800 rpm in order to eliminate the cell-toxic DMSO. 
The cell pellet is resuspended in 10 mL of PrimFibM and seeded into a T75 flask/ø10 cm 
petri dish.  
 
All the experiments with primary fibroblasts were conducted under three different 
conditions: non-treated (N), galactose (GAL) and dexamethasone (DEX). The metabolic 
(GAL, 10 mM) or hormonal (DEX, 1 µM) stress inducing media are applied for 1 week 
under the culturing conditions as described above. 
 
3.2.3 Automated cell counting with CASY Cell Counter 
For accurate cell counting, 60 µL of the cell suspension are diluted in 6 mL CASYton buffer 
and measured automatically. The program determines average cell size, cell viability, total 
cell number and number of viable cells. The amount of viable cells is used for calculations 
of desired numbers of cells used in the experiments.  
 
3.3 Reprogramming of adult human dermal fibroblasts into induced 
pluripotent stem cells using Epi5 plasmids  
3.1 Coating with Vitronectin 
15 µL hrVitronectin XF (250 µg/µL) are diluted in 6 mL PBS and 1 mL per 6-well-plate is 
prepared and polymerized for 1 h at room temperature. The wells are washed with 2 mL 
of PrimFibM before seeding the cells and 2 mL fresh PrimFibM are added to each well of 
a 6-well-plate. Per cell line one 6-well-plate is required. 
 
3.2 Preparation of Epi5 plasmids 
For the reprogramming, the VPD-1001 kit (Lonza; Basel, Switzerland) is used. The 
required plasmids are pCBX-EBNS, pCE-hsk, pCE-hUL, pCE-hOCT3/4 and pCE-mp53DD, 
as described in the publication of Takahashi and Yamanaka 2006. 600 ng of each plasmid 
are required. The plasmids are mixed with 82 µL of nucleofactor solution and 18 µL of the 
supplement. 
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3.3 Preparation and electroporation of human fibroblasts 
The fibroblasts are split and counted as described in the previous chapter. The cell pellet 
of 600,000 cells is washed once with 3 mL of PBS in order to remove remaining PrimFibM. 
The cells are centrifuged again at 800 rpm for 5 min. The medium is aspirated and the 
cells are mixed with the solution containing the plasmids and the nucleofactor solution. 
The cell suspension is applied into the pre-cooled electroporation chambers. The cells are 
electroporated with program U-23 of the Amaxa Nucleofactor Electroporator (Lonza; 
Basel, Switzerland) and immediately put back on ice. 200 – 300 µL of PrimFibM are added 
to the cell suspension and it is distributed equally drop by drop into the 6 wells of the 6-
well-plate. Day 0 and day 1 after electroporation PrimFibM with 100 µg of sodium 
butyrate is used. From day 2 on until day 7, E7 Medium with 100 µM sodium butyrate is 
applied and the medium is changed every day. From day 8 on, E7 Medium without sodium 
butyrate is used and the medium is changed every day. From day 15, on clones should 
appear. The clones are marked with self-inking object  marker  (‘’cell dotter’’) (Nikon; 
Tokyo, Japan) and picked with the help of a digital microscope (Primo Vert, Zeiss; 
Oberkochen, Germany) under sterile conditions and transferred into a new well of a 12-
well-plate each by taking up the clone with a 200 µL tip. The 12-well-plates are coated 
with Matrigel beforehand as described in the following chapter.  
 
 
3.4 Coating for iPSCs and NPCs  
iPSCs and NPCs require coated plates for attachment and optimal growth. Matrigel is a 
soluble basement membrane extract of the Engelbreht-Holm-Swarm (EHS) tumor that 
polymerizes to form a reconstituted basement membrane (Kleinman et al., 1986). An 
aliquot Matrigel (volume dependent on manufacturer’s advice, usually 270 µL – 300 µL) 
is dissolved in cold 12 mL DMEM/F12 and for each well this solution and cold DMEM/F12 
are added 1:1 into the pre-cooled plate. Afterwards, the plates can be stored for one to 
three weeks at 4 °C or polymerized at 37 °C for 30 min. Before the cell suspension is added 
to the wells, they need to be washed with DMEM/F12 in order to remove unpolymerized 
Matrigel. The table below lists the volumes required for the different plates. In case cover 
slips are added to the wells, they are placed into the wells before the solutions are added. 
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Table 18 Coating conditions 
Plate type DMEM/F12 with Matrigel DMEM/F12 
6-well-plate 1 mL 1 mL 
12-well-plate 0.5 mL 0.5 mL 
24-well-plate 250 µL 250 µL 
XFp Seahorse Miniplate 100 µL 100 µL 
 
 
3.5 Induced pluripotent stem cells  
3.5.1 Culturing conditions 
The iPSCs are kept under standard conditions (37 °C, 5% CO2). The mTeSR Medium is 
changed every day and differentiated parts are marked and aspirated. 
 
3.5.2 Passaging, freezing and thawing procedure 
One well of a 6-well-plate of iPCSs is split in a 1:3 ratio. 6-well-plates are coated as 
described above and 1.5 mL of mTeSR Medium are put into each well. The medium is 
aspirated and per each 6 well 1 mL of pre-warmed Dispase is added. After 5 to 8 min the 
Dispase is aspirated and each well is washed three times with 1 mL of DMEM/F12. After 
the last washing step, 2 mL of DMEM/F12 is added and the previously marked 
differentiated spots and finally the DMEM/F12 are aspirated.  1.5 mL of mTeSR Medium 
are added. With the help of a disposable glass pipette the stem cell colonies are separated 
by gently scratching the bottom in grid pattern. With the help of a cell scraper the stem 
cell colonies are completely detached from the bottom. Per each new well, 0.5 mL of the 
cell suspension are added drop by drop and distributed by gently shaking horizontally. 
 
For freezing purposes, after detaching the cells with the help of Dispase and the 
differentiated cells are removed as described before. The cells are detached with a cell 
scraper in DMEM/F12 and transferred into a 15 mL Falcon tube and centrifuged at 
800 rpm for 5 min. The cell pellet is taken up in 1 mL CryoStore CS10 freezing medium, 
put into a cryo vial and stored at -80 °C. 
 
For thawing, the cryo vial with the stem cells is put into a waterbath (37 °C) for maximum 
5 min and the cell suspension is quickly transferred into a 15 mL Falcon tube containing 
3 mL of DMEM/F12 in order to remove the cytotoxic component of the freezing medium. 
The suspension is centrifuged for 5 min at 800 rpm, the supernatant is aspirated and the 
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cell pellet is taken up into 2 mL of mTeSR Medium and seeded onto one well of a 6-well-
plate. 
 
3.6 Neural induction and expansion of neural progenitor cells 
One day after splitting, the iPSC colonies for differentiation should have densities of 2–
2.5x104. mTeSR Medium is changed to Neural Induction Medium (NIM). The medium is 
changed every other day from day 0 until day 4 of neural induction and from day 5 on 
every day, since cell densities increase during differentiation. After one week, the cells are 
split. The cells are detached with 1 mL pre-warmed Accutase for 5 min per one 6-well. 
The reaction is stopped by adding 2 mL of DPBS or DMEM/F12. The suspension is 
transferred into a 15 mL Falcon tube and centrifuged for 5 min at 800 rpm. The 
supernatant is aspirated and the cell pellet is resuspended in 2-3 mL of DPBS or 
DMEM/F12 and the suspension is passed through a 100 µm cell strainer placed on a 50 
mL Falcon tube. Subsequently, the suspension is centrifuged at 800 rpm for 5 min and the 
cell pellet is resuspended in Neural Expansion Medium (NEM) with 5 µM ROCK-Kinase-
Inhibitor. The cells are counted with the help of Trypan Blue in a Neubauer Chamber and 
approximately 6.0–7.0x105 cells are seeded onto one well of a 12-well-plate coated with 
Matrigel. The medium is changed every other day and the NPCs of passage 0 are grown 
until they reach confluence.  
 NPCs are split by aspirating the medium and the addition of 1 mL pre-warmed Accutase 
for 5 min. The reaction is stopped by 2-3 mL of DPBS or DMEM/F12 and the cell 
suspension is transferred into a 15 mL Falcon tube and centrifuged at 800 rpm for 5 min. 
The supernatant is aspirated and the cell pellet is resuspended in 5 mL DPBS or 
DMEM/F12 and 20 µL are mixed with 20 µL of Trypan Blue in a 1.5 mL Eppendorf cup 
and used for counting with the Neubauer Chamber. 2-3 mio cells are seeded into a well of 
6-well-plate coated with Matrigel. 5–6x106 cells are used for freezing. The volume of cell 
suspension with the desired amount of cells is transferred into a new 15 mL Falcon tube 
and centrifuged down at 800 rpm for 5 min. NPCs used for cultivation are resuspended in 
NEM and seeded. NPCs that are being frozen are taken up into 1 mL of STEMdiff Neural 
Progenitor Freezing Medium, transferred in to a 2 mL cryo vial and stored at -80 °C, 
respectively at -196 °C.  
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NPCs are thawed by putting the cryo vial for maximal 5 min into the waterbath (37 °C) 
and transferring the cell suspension into 2-3 mL of DPBS or DMEM/F12. The cell 
suspension is centrifuged at 800 rpm for 5 min in order to remove the potentially 
cytotoxic residuals of the cryo storage medium. The cell pellet is resuspended in 2 mL 
NEM and the cell suspension is seeded onto one well of a 6-well-plate coated with 
Matrigel. 
 
3.7 Immunocytochemical staining 
For immunocytochemical staining, the cells are split and seeded onto cover slips, in low 
densities with approximately 60% confluence. The next day, the cover slips are 
transferred into a new plate and the cells are fixed with 4% PFA for 10 min. Subsequently, 
in each well 250 µL blocking buffer are added in order to prevent unspecific binding of 
the antibody. Afterwards, the first antibody is applied and left over night at 4 °C. The next 
day, the antibody is discarded and the coverslips are washed three times with 500 µL 1X 
PBS for 10 min. The second antibody is applied for 1 h at RT in the dark. The second 
antibody is discarded and the coverslips are washed again three times with 1X PBS for 10 
min. The coverslips are mounted onto glass object slides with the help of a drop of Dako 
Fluorescing Mounting Medium and let to polymerize overnight. 
 
3.8 Assessment of respiratory properties: Seahorse XFp Flux Analyzer  
For respiratory experiments, the cells are being split and seeded as described beforehand 
the day before the experiment. 30,000 fibroblasts or 500,000 NPCs, respectively, are 
seeded into the wells of the XFp Seahorse Miniplate. The Wells B to G contain control cells 
respectively patient cells in triplicates. The wells A and H remain without cells as a blank 
control.  
Additionally, an XFp Flux Cartridge is equilibrated with 200 µL in the wells A to H and 400 
µL of Agilent Seahorse XF Calibrant solution in the outer cambers and left at 37 °C in a 
non-CO2 incubator. 
The following day, the XFp Seahorse Miniplate containing the cells is washed with 200 µL 
of Seahorse Assay Medium, finally filled with 180 µL of the Seahorse Assay Medium and 
left for 30 min to 1 h in a non-CO2 incubator. Meanwhile, the reagents for the XFp Mito 
Stress Test are being prepared. Therefore, the component stocks are diluted 1:1000 in 
Seahorse Assay Medium and applied into the Seahorse XFp Flux Cartidge into different 
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volumes in order to get a final concentration of 1 µM Oligomycin, 2 µM FCCP and 0.5 µM 
Rontenone/Antimycin A. 
 
 
Figure 9 ETC inhibitors. Inhibition of the ETC is sequentially conducted in Seahorse XFp Flux experiments. 
Oligomycin acts on Complex V, the ATP synthase, and inhibits the degradation of the H+ gradient. FCCP is an 
uncoupler of the ETC and enables and uninhibited flow of the H+. Rotenone and Antimycin A block Complex I and 
Complex III of the ETC and shut down OXPHOS. 
 
 
20 µL Oligomycin are applied into all of the ‘’A’’ ports, 22 µL FCCP are pipetted into ports 
‘’B’’ and 25 µL of the Rotenone/Antimycin A mixture are added into the ports ‘’C’’ in all of 
the wells A to H of the Seahorse XFp Flux Cartidge.  
The Seahorse XFp Flux Cartidge is placed into the XFp Flux Analyzer for calibration and 
afterwards, the cells are placed into the machine, according to the manufacturer’s 
instructions and the XFp Mito Stress Test is started. For the Mito Stress Test, four baseline 
measurements of the OCR and the ECAR are conducted and four measurements each are 
made after the sequential injection of the components (see figure 9). The assay output 
includes also an overall mean OCR value and mean ECAR value calculated from all 16 
measured points. 
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Figure 10 Mito Stress Test in the Seahorse XFp Flux Analyzer. Initially, the basal respiration is measured. By the 
inhibition of the ATP synthase by Oligomycin the OCR declines. The ATP production-related OCR and the proton 
leak can be determined. FCCP uncouples the ETC and OXPHOS can run at its maximum. The readout parameter 
of the maximal respiration can be assessed. Rotenone and Antimycin A block the ETC and the remaining OCR is 
related to non-mitochondrial processes that require oxygen. The spare capacity results out of the maximal 
respiration subtracted by the basal respiration. 
 
 
After the measurement, the assay medium is aspirated and the fibroblasts are fixed with 
4% PFA for 10 min for normalization purposes with Hoechst staining. The NPCs are stored 
at -20 °C and normalized by determination of the protein content with the BCA Assay (see 
3.10). 
 
3.10 Normalization of respiratory experiments 
3.10.1 Normalization by Hoechst staining 
When XFp Mito Stress Test of fibroblasts is finished, the medium is aspirated and the cells 
are fixed with 100 µL 4% PFA per XFp Seahorse Miniplate-well for 10 min. The cells are 
washed with 200 µL PBS and stained with Hoechst (1:1000 in PBS) for 10 min in the dark 
and washed with 200 µL PBS three times in order to remove residual dye. With the help 
of a fluorescence microscope pictures of the Miniplate-wells are taken that can be further 
used for cell counting with Image J. The cell numbers per Miniplate-well are entered into 
the Wave files that are created by the XFp Flux Analyzer. 
 
3.10.2 Normalization by Bichinoic Acid Assay 
Following the XFp Mito Stress Test of NPCs, the medium is aspirated and the cells are 
lysed in 20 µl 1X Triton X-100 for 15 min at 4 °C. Meanwhile, 10 µL of BSA standards 
dissolved in 1X Triton X-100 with concentrations reaching from 100 µg/mL to 2 mg/mL 
BSA. The standards are applied onto a transparent 96-well-plate. The reagents A and B 
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are used in a ratio 1:50. 200 µL of the AB-reagent is applied to each Miniplate-well and 
the cells are resuspended properly. Twice 110 µL of the suspension are added to the 96-
well-plate and 100 µL A-B-reagent are added to the cell suspension.  200 µL AB-reagent 
are added to the BSA standards. The plate is shaken for 5 min at RT and incubated for 
30 min at 37 °C in a non-CO2 incubator. The absorption is measured in a VarioScan plate 
reader and analyzed with the Software SkanIt. The protein content (mg/mL) is 
determined with the help of the BSA standards for each well and used for normalization 
of the respiratory experiments. The resulting protein amounts are added to the Wave files 
containing the results of the Mito Stress Test. 
 
 
3.11 Luminescent assay for ATP content 
For the determination of the ATP content, 1x105 fibroblasts and 1x106 NPCs cell pellets 
are collected in a 1.5 mL Eppendorf cup and stored at -20 °C if necessary. Untreated or 
previously treated fibroblasts with galactose (10 mM, 7 days) or dexamethasone (1 µM,  
7 days) and untreated or previously with dexamethasone treated (1 µM, 7 days) NPCs are 
used for ATP content determination.  
According to the manufacturer’s advice, the CellTiter-Glo®Reagent containing 
CellTiter®Substrate and CellTiter®Buffer, is thawed on ice. As an ATP standard curve 
with concentrations of 10 µM, 100 nM, 10 nM and 10 pm ATP in PBS is used. The cell 
pellets are resuspended in 500 µL PBS and heated at 100°C for 2 min in order to inactivate 
ATPases. Subsequently, the samples are stored on ice. 50 µL of each sample and each 
standard are applied to a black 96-well-plate in duplicates. 50 µL of the CellTiter-
Glo®Reagent are added to the ATP standards and the samples and the 96-well-plate is 
shaken for 2 min in the dark. The absorption is measured at the VarioScan with an 
integration time of 1 s. The RLU generated by the SkanIT Software can be calculated to the 
actual ATP concentrations with the help of the ATP standard curve.  
 
 
 
Figure 11 Luciferase reaction for ATP quantification. Mono-oxygenation of luciferin is catalyzed by luciferase in the 
presence of Mg2+, ATP and molecular oxygen. Source: CellTiter-Glo®Assay Technical Manual, Promega 
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3.12 Live cell imaging 
Live cell imaging experiments are conducted with a Zeiss Axio Observer Z.1 microscope 
equipped with Fluar 40/1.3 objective lens (Zeiss; Oberkochen, Germany) and a Lambda 
DG-4 excitation device (Sutter Instruments; Novato, California). All recordings are 
conducted at a magnification of 40X with oil and captured with an AxioCam MRm CCD 
camera (Zeiss; Oberkochen, Germany). Hardware control and measuring parameters are 
set with the help of ZEN 2012 Software. Fibroblasts and NPCs used in imaging 
experiments are either non-treated (N) or underwent metabolic (GAL) or hormonal stress 
(DEX) for one week. 
 
3.12.1 Mitochondrial membrane potential measurements with JC-1 
The cationic dye JC-1 allows the qualitative measurement of the MMP in different cell 
types. The dye exhibits a potential-dependent accumulation in mitochondria, indicated by 
a fluorescence emission shift from green (~529 nm) to red (~590 nm). Consequently, 
mitochondrial depolarization is indicated by a decrease in the red/green fluorescence 
intensity ratio. The potential-sensitive color shift from green fluorescing monomers of the 
dye is due to concentration-dependent formation of red fluorescent aggregates. 
 
 
 
Figure 12 Emission spectra of the cationic dye JC-1. Depending on the mitochondrial membrane 
potential, JC-1 dye is present as monomers or forms aggregates. The monomers emit at 529 nm, 
whereas aggregates of the dye emit at 590 nm. The ratio between red/green is associated with the 
mitochondrial membrane potential. Source: https://www.biotek.de/de/resources/application-
notes/fluorescent-detection-of-drug-induced-mitochondrial-toxicity/ 
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The JC-1 dye is used at a final concentration of 300 nM in OptiMEM and the cells are 
incubated with the dye for 30 min.  The cells are washed three times with Ringer’s solution 
and the cover slip is placed in the measuring chamber. The cells are covered with 200 – 
300 µL of Ringer’s solution. 5-10 visual fields are captured at a 40X magnification with oil. 
The exposure time is set to 150 ms. 5 cycles with 2s each are recorded. Data analysis is 
done with FIJI Image J by defining regions of interest per each picture and Ratio Plus 
Plugin for determination of the red/green ratios.  
 
 
3.12.2 Analysis of intracellular Ca2+ with Fura-2 dye 
For assessment of Ca2+ homeostasis, the fluorescent dye Fura-2/AM (‘’Fura-2’’) is used. 
The emission wavelength of Fura-2 is dependent on the free or Ca2+-bound state of the 
dye. Free Fura-2 emits at 380 nm, Ca2+-bound Fura-2 emits a wavelength of 340 nm. The 
ratio of 340 nm/380 nm is correlated with the amount of cytosolic Ca2+ in the cell.  
 
 
 
 
Figure 13. Emission spectra and complex forming of the ratio metric dye Fura-2. In the presence of Ca2+ Fura-2 
forms a chelate complex and changes its conformation. Free Fura-2 is excited at 340 nm, whereas Ca2+-bound 
Fura-2 is excited at 380 nm. Both forms emit at 510 nm. The ratio between 34 0nm/380 nm is directly related to free 
cytosolic Ca2+ in the cell. Source: https://www.moleculardevices.com/products/assay-kits/gpcrs/fura-2-qbt-calcium-
kit#Technology 
 
 
Fibroblasts and NPCs are split and prepared for the measurements the previous day. The 
cells are plated onto 25mm cover slips. For NPCs coating with Matrigel is required as 
described before. 150,000 fibroblasts or 2.8 Mio NPCs are seeded. The following day 1 µL 
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Fura-2 dye is mixed with 1 µL Pluronic 10% F127 and diluted in 1 mL OptiIMEM (final 
concentration 2 µM). The cover slip is transferred into a 35 mm tissue dish, the solution 
with the dye is added and incubated for 30 mins. The cells are washed with Ringer’s 
solution three times and the cover slip is applied onto the measuring chamber. The cells 
are covered with 200 – 300 µL Ringer solution. The measurements for Ca2+ are conducted 
at a Zeiss fluorescent microscope with the help of Zen software. For each cover slip 5 – 15 
different sections with cells are measured. 5 cycles for 2 s each, with an exposure time of 
300 ms (fibroblasts) or 150 ms (NPCs) for both channels are recorded at a 40X 
magnification with oil. 
The analysis of the measurements is done with FIJI Image J, by manual definition of the 
regions of interest and building the 340 nm/380 nm ratio for each image. 
 
3.13 Determination of the mitochondrial content 
3.13.1 gDNA extraction 
For each patient and control cell line gDNA was extracted from two biological replicates. 
The cell pellet of 1x106 cells is resuspended in 200 µL PBS and 20 µL QIAGEN Protease is 
added. Afterwards, 200 µL of AL buffer is added to each sample and vortexted for 15 s to 
ensure proper mixing. The samples are incubated at 56 °C for 10 min. 200 µL ethanol 
(100%) are added to the sample and again mixed by pulse-vortexing for 15 s. After mixing, 
the tube is briefly centrifuged to remove drops from the inside of the lid. Subsequently, 
the mixture is applied to the QIAamp Mini spin coloumn placed in a 2 mL collection tube 
without wetting the rim. Cap closed, the samples are centrifuged at 8000 rpm for 1 min. 
The QIAamp Mini spin column is changed to a new collection tube and the tube with the 
filtrate is discarded. In the next step, 500 µL AW1 buffer is applied and the samples are 
centrifuged at 8000 rpm. Afterwards, the QIAmp Mini spin column is changed to a new 2 
mL collection tube and the filtrate and the old collection tube can be discarded. The second 
washing AW2 buffer is applied to the sample (500 µL) and the QIAamo Mini Spin columns 
are centrifuged at full speed (14000 rpm for 5 min). In order to remove remaining 
washing buffer, the QIAamp Mini columns are placed into a fresh collection tube and 
centrifuged at full speed for 1 min. The QIAamp Mini Spin columns are then placed into a 
fresh 1.5 mL Eppendorf cup and to each sample 100 µL of distilled water are added. After 
an incubation time of one minute at RT (15-25 °C) the gDNA is eluted at 8000 rpm for 1 
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min. The DNA concentration is determined at the Nano Drop and all the samples are 
adjusted to 50 ng/µL for RT-PCR measurements. 
 
3.13.2 Quantitative Real-Time Poly Chain Reaction 
3.13.2.1 Amplification efficiencies 
 
For the quantification of the mtDNA content, the primers for the mitochondrial gene 
mt-TL1 and the nuclear gene B2M are used. Primer sequences are listed in table 19. 
 
Table 19 Target genes, sequences, concentrations and manufacturer of the primers used for mtDNA 
quantification 
Gene Abbr. direction Sequence Stock conc. Manufacturer 
Beta-2 
microtubulin 
B2M forward 5′-
TGCTGTCTCCA
TGTTTGATGTA
TCT 
10 µM Metabion, Planegg, 
Germany 
reverse 5′-
TCTCTGCTCCC
CACCTCTAAGT 
mitochondrially 
encoded tRNA 
leucine 1 
mt-TL1 forward 5′-
CACCCAAGAAC
AGGGTTTGT 
10 µM Metabion, Planegg, 
Germany 
reverse 5′-
TGGCCATGGGT
ATGTTGTTA 
 
 
In order to test the primer efficiency first, five times a threefold serial dilution of one DNA 
sample in water is made. The dilutions are used to obtain a standard curve and the PCR 
efficiency (E) is determined. PCR efficiency is calculated from the slope of the standard 
curves using the equation formula: 
 
E = 10-1/slope – 1 
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In order to improve precision, the samples for the standard curve were pipetted in 
quadruplicates. 
 
 
  
c target dye slope intercept R2 efficiency 
 mtDNA FAM -3.448 11.172 0.99343 0.95 
 nDNA YY -3.463 18.615 0.98445 0.94 
Figure 14 Graphs and values for primer efficiency for mtDNA copy number determination. Regression curve, R2 
and efficiency determination for (a) mtTL1 primer pair and (b) B2M primer pair. In the table (c) below, the values 
for slope, intercept, R2 and efficiency for each target are listed. 
 
The components and volumes for each single RT-PCR reaction is listed in table 20. The 
RT-PCR is run in an initial phase of 5 min at 95 °C, followed by 45 cycles of 95 °C for 15 s 
and 60 °C for 30 s. The melt curve is assessed from 65 °C to 95 °C. 
 
Table 20 Ragencies and volumes for RT-PCR 
Reagent Volume 
gDNA 50 ng/ µL 0.5 µL 
primer forward 0.5 µL 
primer reverse 0.5 µL 
H20 3.5 µL 
 
3.13.2.2 mtDNA copy number calculation 
 
Relative quantification was applied to calculate number of mtDNA per diploid nuclear 
(2n) cell: 
2 x E-𝝙𝝙Cq 
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In this equation ‘’Cq’’ is the quantification cycle, 𝝙𝝙Cq is (Cqmt-Cqnuc), ‘’E’’ is the averaged 
mean efficiency of the PCR reactions of the two targets and ‘’2’’ is to account for the two 
nDNA copies in a cell (Fazzini et al. 2018). The mtDNA copy number was assessed from 
two biological replicates for each cell line and each biological replicate was measured in 
two separate runs. 
 
3.14 Data analysis and statistics 
Data collection and calculations are done with Windows EXCEL (Microsoft Corporation; 
Redmond, Washington). Graphical depiction and statistical analysis is conducted with 
Graph Pad Prism 8.0.2 (GraphPad Software; San Diego, California).  
For all analysis, the mean of two to three technical replicates is calculated and two or three 
biological replicates are averaged. All data is checked for normality and lognormality 
(Anderson-Darling test, D’Agostnino & Pearson test, Shapiro Wilk test and Kolmogorov-
Smirnov test). Consequently, the parametric test (Student’s paired t-test) or non-
parametric test (Wilcoxon matched-pairs rank sum test) are applied. P-value limit for 
statistical significance is set to ≤ 0.05. Values are given as means ± standard error of the 
mean (SEM). Energy maps are statistically evaluated by ANOVA with repeated measures 
and Greenhouse Geisser as a Post Hoc Analysis respectively Bonferroni correction. 
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4 Results 
4.1 Patient and control cohort 
 
To exclude gender- and age-specific differences in mitochondrial and respiratory 
functions, for each patient a matching control was recruited. As depicted in Table 21, 
patients and controls do not differ in mean age or sex. The patients’ age ranges from 21 to 
50 with a mean age of 31±3.12 and the controls are aged 19 to 49 with a mean age of 
32±2.81. Eleven male patients and five female patients were paired with eleven male 
healthy controls and five healthy female controls. Moreover, physical parameters were 
assessed. Patients and controls do not differ in BMI (patients BMI = 23.0±0.48; controls 
BMI = 24.2±03.28). Whereas 94% of the MDD patients smoke, 25% of the controls exhibit 
a regular smoking habit. 56% of the patients drink regularly alcohol, whereas 94% of the 
healthy controls declared that they consume alcohol several times a week. 93% of the 
MDD patients and 83% of controls do not consume drugs. Drug abuse in controls was 
stated as ‘’very seldom’’. Besides physiological examinations psychological health of the 
controls was confirmed by PD Dr. med. Caroline Nothdurfter (Berzirksklinikum 
Regensburg) to exclude possible mental diseases (HAM-D 0-3). The patient cohort for this 
study was selected according to their diagnosis at the Bezirksklinikum Regensburg. All 
patients were diagnosed according to ICD-10 with a medium severe or severe MDD (HAM-
D 20-34, please see method section 3.1). All patients were treated with different 
combinations of ADs. The ADs given are listed in the table below. 
 
 
Table 21 Mean and SEM of clinical characteristics of n=16 MDD patients and n=16 controls. 
Variables 
 
Groups 
MDD (n=16) Controls (n=16) 
 
ICD-10 
 
F32.1 
F32.2 
F33.1 
F33.3 
 
 
 
2 
10 
1 
3 
 
 
 
0 
0 
0 
0 
Age (mean ± SEM, years) 
 
31 ± 3.12 
 
11 (69%)/5 (31%) 
32 ± 2.81 
 
11 (69%)/5 (31%) 
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Sex (male, n (%)/female, n 
(%)) 
 
BMI (mean±SEM, kg m -2) 
 
Smoker (yes, n (%)) 
 
 
Alcohol (yes, n (%)) 
 
 
Drugs (no, n (%)) 
 
 
 
23.0 ± 0.48 
 
9 (75%) 
[4 n/a] 
 
9 (75%) 
[4 n/a] 
 
11 (93%) 
[4 n/a] 
 
 
24.2 ± 3.38 
 
4 (25%) 
 
 
15 (94%) 
 
 
13 (81%) 
Medication 
 
Agomelatin 
Bupropion 
Duloxetin 
Escitalopram 
Mirtazapin 
Olanzapin 
Promethazin 
Trimipramin 
Venlafaxin 
 
 
 
 
3 
2 
1 
6 
3 
2 
1 
1 
2 
 
 
0 
0 
0 
0 
0 
0 
0 
0 
0 
 
 
4.2 Differences in mitochondrial metabolism in peripheral cells: Fibroblasts 
show alterations in mitochondria-related functions 
 
Human dermal fibroblasts are easily accessible, fast growing and simple to cultivate. 
Despite the fact, that the cells are not of neural origin, it already could be shown that 
peripheral cells (PBMCs, platelets or muscle cells) from people suffering from psychiatric 
disorders - like MDD and PTSD - harbor alterations in their cellular metabolism (Garbett 
et al. 2015; Gardner et al. 2003; Hroudová et al. 2013; Karabatsiakis et al. 2014). 
Therefore, experiments with human dermal fibroblast are the initial approach to 
investigate mitochondria-related changes in association with MDD. The results regarding 
the patient cohort and experiments with fibroblasts - including respiration, energy maps, 
ATP levels as well as imaging experiments (JC-1 and cytosolic Ca2+ levels) and mtDNA 
content - have previously been published in Kuffner et al. (Kuffner et al. 2020). 
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4.2.1 Mito Stress Test: ETC function and glycolysis 
4.2.1.1 Respiration of fibroblasts 
 
In order to test the mitochondrial function in fibroblasts, each patient cell line was 
examined in comparison to the control cell line. In total, 16 patient cell lines were 
compared to 16 gender- and age-matched cell lines. The cells were measured under 
standard culturing conditions (non-treated), but also after the exposure to one week of 
either hormonal stress induced by DEX or metabolic stress which is evoked by the 
exchange of glucose to galactose in the culture medium. The cellular respiration in form 
of OCR and the measure for the function of the glycolysis, the ECAR, was assessed in the 
XFp Flux Analyzer. The Mito Stress Test allows a readout of various parameters linked to 
the function of the ETC. By the application of compounds interacting with the ETC, the 
basal respiration, the maximum respiration, the spare capacity, the non-mitochondrial 
respiration, the ATP production-related oxygen consumption and the proton leak were 
determined.  
The assessment of the respiratory parameters resulted in significant differences in 
peripheral cells (figure 15). Fibroblasts derived from MDD patients compared to 
fibroblasts from healthy controls have a significantly lower basal respiration under basal 
conditions (MDD 16.09±0.88, CON 18.53±0.95, Student’s t-test, paired, two-tailed, * p > 
0.05, p = 0.0200, mean±SEM). The differences that were detected under basal conditions 
are reversed after one week of stress. The basal respiration after hormonal stress induced 
by DEX does not show differences between MDD cells and cells from controls (MDD 
22.96±1.14, CON 23.25±1.12, Student’s t-test, paired, two-tailed, p = 0.7392, mean±SEM, 
figure 15 a). The application of galactose medium for one week, which demonstrates 
metabolic stress for the cells, also abolished the significant differences between cells from 
patients and healthy subjects (MDD 22.31±1.70, CON 22.64±1.58, Student’s t-test, paired, 
two-tailed, p = 0.7899, mean±SEM, figure 15 a). The maximum respiration is an important 
measure to determine how much the cells could respire in case of an energetic challenge 
or a high energetic demand. In the Mito Stress Test it is induced by the ETC uncoupler 
FCCP. For the maximal respiration similar observations are made. Whereas cells from 
healthy controls reach significantly higher OCRs than MDD cells under non-treated 
conditions (MDD 32.20±2.23, CON 37.01±2.40, Student’s t-test, paired, two-tailed, *** p < 
0.001, p = 0.0003, mean±SEM, figure 15 b), the detected differences are not present after 
DEX stress (MDD 48.76±3.88, CON 45.03±2.32, Student’s t-test, paired, two-tailed, 
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p = 0.4514, mean±SEM, figure 15 b) neither after galactose stress (MDD 57.86±2.64, CON 
60.04±3.51, Wilcoxon matched-pairs signed rank test, p = 0.2769, mean±SEM, figure 15 
b). A parameter that is closely related to the basal respiration and the maximal respiration 
is the spare respiratory capacity. The spare respiratory capacity is a measure for the cells 
flexibility and ability to react to an excess energetic need. Theoretically, the higher the 
spare capacity the more reserves the cells have in case of an energetic challenge. 
Accompanying the results from basal respiration and the maximal respiration, the MDD 
cells also show significant differences in the spare respiratory capacity under normal, 
non-treated conditions (MDD 16.11±1.81, CON 18.95±2.29, Student’s t-test, paired, two-
tailed, * p < 0.05, p = 0.0257, mean±SEM, figure 15 c).  The spare respiratory capacity did 
not differ between MDD fibroblasts and fibroblasts derived from healthy controls after 
hormonal stress (DEX, MDD 25.28±3.15, CON 27.72±3.92, Wilcoxon matched-pairs signed 
rank test, p = 0.2769, mean±SEM) or after metabolic stress (GAL, MDD 35.91±3.19, CON 
37.33±3.65, Wilcoxon matched-pairs signed rank test, p = 0.2078, mean±SEM, figure 15 
c). Furthermore, the non-mitochondrial respiration was determined after the application 
of Rotenone and Antimycin A that block the Complex I and III of the ETC and therefore 
inhibit mitochondrial respiration. The non-mitochondrial respiration is caused by other 
enzymatic reactions in the cell or oxygenases outside the mitochondria. MDD fibroblasts 
exhibit a significantly lower non-mitochondrial respiration under normal conditions in 
comparison with control fibroblasts (MDD 7.90±0.71, CON 9.650.91, Student’s t-test, 
paired, two-tailed, * p < 0.05, p = 0.0115, mean±SEM), indicating an overall decreased 
cellular metabolism. These alterations are cancelled out after one week of DEX stress 
(MDD 11.08±0.95, CON 11.84±0.79, Student’s t-test, paired, two-tailed, p = 0.2134, 
mean±SEM) but not by metabolic stress (MDD 15.43±1.34, CON 18.05±1.60, Student’s t-
test, paired, two-tailed, * p < 0.05, p = 0.0818, mean±SEM, figure 15 d). 
 
Oligomycin blocks the ATP synthase and allows the proton leak and the ATP-related OCR 
as readout parameters in the Mito Stress Test. Oligomycin prevents the increase in 
mitochondrial respiration induced by ADP without inhibiting uncoupling-stimulated 
respiration. NADH remains high and NAD+ is too low for the citric acid cycle to operate (O. 
Lee, P.J. O’Brien, 2010). The proton leak describes the flux of H+ across the mitochondrial 
membrane independently from the ETC, but through transporters, for example (Cheng et 
al. 2017). No significant differences were detected in the proton leak-associated OCR 
neither under non-treated conditions (MDD 2.38±0.20, CON 2.80±0.22, Student’s t-test, 
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Figure 15 Seahorse XFp Flux Analyzer results of fibroblasts. (a) Shown is the basal respiration in fibroblasts of 
MDD and control cell lines under non-treated conditions and after one week of 1 µM DEX or 10 mM GAL stress. 
Significant differences were found for MDD vs. control, non-treated (* p < 0.05, compared with control, Student’s t-
test, paired, two-tailed). (b) Shown is the maximal respiration in fibroblasts of MDD and control cell lines under non-
treated conditions and after one week of 1 µM DEX or 10 mM GAL stress. Significant differences were found for 
MDD vs. control, non-treated (*** p < 0.001, compared with control, Student’s t-test, paired, two-tailed). (c) Shown 
is the spare respiratory capacity in fibroblasts of MDD and control cell lines under non-treated conditions and after 
one week of 1 µM DEX or 10 mM GAL stress. Significant differences were found for MDD vs. control, non-treated 
(* p < 0.05, compared with control, Student’s t-test, paired, two-tailed). (d) Shown is the non-mitochondrial 
respiration in fibroblasts of MDD and control cell lines under non-treated and after one week of 1 µM DEX or 10 mM 
GAL stress. Significant differences were found for MDD vs. control, non-treated (* p < 0.05, compared with control, 
Student’s t-test, paired, two-tailed) and GAL (* p < 0.05, compared with control, Wilcoxon matched-pairs signed 
rank test). (f) Shown is the proton leak in fibroblasts of MDD and control cell lines under non-treated conditions and 
after one week of 1 µM DEX or 10 mM GAL stress. No significant differences were found. (g) ATP production in 
fibroblasts of MDD and control cell lines under non-treated conditions and after one week of 1 µM DEX or 10 mM 
GAL stress. Significant differences were found for MDD vs. control, non-treated (* p < 0.05, compared with control, 
Student’s t-test, paired, two-tailed). Bar graphs show normalized mean OCR values + SEM; MDD n=16, control 
n=16. 
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paired, two-tailed, p = 0.2041, mean±SEM, figure 15 e), nor under DEX stress (MDD 
2.94±0.31, CON 2.72±0.29, Student’s t-test, paired,  two-tailed, p = 0.2415 mean±SEM, 
figure 15 e) neither GAL stress (MDD 3.99±0.58, CON 3.76±0.37, Student’s t-test, paired, 
two-tailed, p = 0.5415 mean±SEM, figure 15 e). Nevertheless, control fibroblasts show 
under normal conditions a higher ATP-related OCR compared to MDD fibroblasts (MDD 
13.71±0.76, CON 15.72±0.82, Student’s t-test, paired, two-tailed, * p < 0.05, p = 0.0257, 
mean±SEM, figure 15 f), but not subsequent to exposure of DEX (MDD 19.91±0.90, CON 
20.52, Student’s t-test, paired, two-tailed, p = 0.4110, mean±SEM, figure 15 f) or GAL 
(MDD 18.32±1.26, CON 18.88±1.27, Student’s t-test, paired, two-tailed, p = 0.5847, 
mean±SEM, figure 15 f).  
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Figure 16 Mito Stress Test in fibroblasts. 
Exemplary curves for OCR measurement 
during the Mito Stress Test for MDD (white 
squares) and control (black dots) 
fibroblast lines (pair #6). Sequential 
injection of Oligomycin, FCCP and 
Rotenone/Antimycin A causes by 
interaction with the complexes of the ETC 
changes in the OCR. Figure (a) depicts 
graphically the differences in basal 
respiration and maximal respiration after 
injection of FCCP. The lower basal and 
maximal respiration of MDD cells is 
rescinded after one week of (b) 1 µM DEX 
stress or (c) 10 mM GAL stress. 
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4.2.1.2 Energy profile of fibroblasts 
 
Besides the OCR, the Seahorse XFp Flux Analyzer assesses the secretion of H+, the ECAR, 
which is a measure for glycolysis. The OCR values in dependence of the ECAR values 
across the entire Mito Stress Test describes the general energetic state of the fibroblasts 
and gives a hint whether the cells metabolism is more driven towards a glycolytic state or 
OXPHOS activity. 
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Figure 17  Energy map of fibroblasts. Mean OCR in dependence of mean ECAR are shown for MDD and control 
fibroblasts for non-treated, after one week of 1 µM DEX and 10 mM GAL stress. Significant effects of treatment 
were found for DEX (# p << 0.05, compared with non-treated, ANOVA with repeated measures, Greenhouse-
Geisser correction, Post-Hoc Analysis with Bonferroni) and GAL (§ p << 0.05, compared with non-treated, ANOVA 
with repeated measures, Greenhouse-Geisser correction, Post-Hoc Analysis with Bonferroni), Data are shown as 
mean OCR±SEM vs. mean ECAR±SEM; MDD n=16, control n=16.  
 
In fibroblasts, the three conditions non-treated (MDD OCR 24.55±1.00 vs. CON OCR 
29.32±1.70 vs. MDD ECAR 13.68±0.99 vs. CON ECAR 12.78±0.7, mean ± SEM), DEX (MDD 
OCR 39.74±3.57 vs. CON OCR 43.62±2.66 vs. MDD ECAR 10.74±1.28 vs. CON ECAR 
11.21±0.9, mean±SEM) and GAL (MDD OCR 49.69±4.58 vs. CON OCR 49.72±3.83 vs. MDD 
ECAR 19.42±2.38 vs. CON ECAR 16.18±1.21, mean±SEM, figure 17) compared to each 
other had significantly different effects (ANOVA with repeated measures, Greenhouse-
Geisser correction, F(2, 64)= 32.904, p << 0.05, df = 2). In particular, DEX had a significant 
effect on OCR and ECAR (N vs. DEX for MDD and CON, Post-Hoc Analysis, Bonferroni 
correction p << 0.05) and GAL stress changed OCR and ECAR significantly (N vs. GAL for 
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MDD and CON, Post-Hoc Analysis, Bonferroni correction p << 0.05). However, the 
conditions with DEX (MDD OCR DEX 39.74±3.57 vs. MDD OCR N 24.55±1.00 vs. CON OCR 
DEX 43.62±2.66 vs. CON OCR N 29.32±1.70, MDD ECAR DEX 10.74±1.28 vs. MDD ECAR N 
13.68±0.99 vs. CON ECAR DEX 11.21±0.97 vs. CON ECAR N 12.78±0.77, mean±SEM, figure 
18 b) and GAL (MDD OCR GAL 49.69±4.58 vs.  MDD OCR N 24.55±1.00 vs. CON OCR GAL 
49.72±3.83 vs. CON OCR N 29.32±1.70, MDD ECAR GAL 19.42±2.38 vs. MDD ECAR N 
13.68±0.99 vs. CON ECAR GAL 16.18±1.21vs. CON ECAR N 12.78±0.77, mean±SEM, figure 
18 c) did not have significantly different effects on the groups (ANOVA with repeated 
measures Greenhouse-Geisser correction, F(2, 64)= 0.788, p = 0.457). The shift towards a 
more aerobic state for DEX and the shift towards a more energetic state is similar in the 
MDD and the control group. The treatment with DEX (MDD OCR 39.74±3.57, MDD ECAR 
10.74±1.28; CON OCR 43.62±2.66, CON ECAR 11.21±0.97; mean±SEM) compared to GAL 
(MDD OCR 49.69±4.58, MDD ECAR 19.42±2.38; CON OCR 49.72±3.83, CON ECAR 
16.18±1.21; mean±SEM) did not have the same effect on OCR respectively ECAR (ANOVA 
with repeated measures Greenhouse-Geisser correction, F(2, 64)= 18.215, p << 0.05, df = 
1.664), which describes that DEX treatment leads to an increase in OCR and therefore 
OXPHOS, but a reduction of ECAR and therefore a decrease in glycolytic activity. GAL 
treatment caused a rise in both, OCR and ECAR and therefore fueled OXPHOS and 
glycolysis.  
Overall, there is no significant difference between the MDD group and the control group 
(ANOVA with repeated measures, Greenhouse-Geisser correction, F(1, 32)= 0.340, p  = 
0.562, df = 1.664). Moreover, the MDD and the control group do not differ significantly 
regarding their OCR (MDD N 24.55±1.00 vs. CON N 29.32±1.70; MDD DEX 39.74±3.57 vs. 
CON DEX 43.62±2.66; MDD GAL 49.69±4.58 vs. CON GAL 49.72±3.83) and their ECAR 
(MDD N 13.68±0.99 vs. CON N 12.78±0.77; MDD DEX 10.74±1.28 vs. CON DEX 11.21±0.97; 
MDD GAL 19.42±2.38 vs CON GAL 16.18±1.21, mean±SEM) values (ANOVA with repeated 
measures Greenhouse-Geisser correction, F(1, 32)= 2.024, p = 0.160, df = 1). 
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4.2.2 ATP content 
Since differences in the respiration of fibroblasts from MDD patients compared to control 
fibroblasts were unraveled, the energy production of mitochondria was examined in 
detail. The main function of mitochondria is the production of energy in form of ATP. In 
the last step of the ETC, the ATP synthase converts ADP and inorganic phosphate to ATP. 
Hence, to test a direct readout parameter of the mitochondrial function and function of 
Figure 18 Energy maps of 
fibroblasts for the three conditions. 
Single OCR values in dependence of 
single ECAR values are shown of 16 
MDD and control pairs for the three 
different conditions (a) non-treated 
(b) after one week of 1 µM 
dexamethasone stress and (c) after 
one week of galactose stress. Due to 
the induction of either hormonal or 
metabolic stress OXPHOS and 
glycolysis are fueled, which can be 
seen in an increase in OCR and 
ECAR values. MDD and control 
fibroblast lines do not significantly 
differ in their OCR and ECAR values 
for any of the conditions (ANOA with 
repeated measures, Greenhouse-
Geisser correction, p > 0.05). 
However, both stressors had 
significant effects on the energetic 
parameters OCR and ECAR in MDD 
and control fibroblast lines (ANOVA 
with repeated measures, 
Greenhouse-Geisser correction, 
p << 0.05). After (b) dexamethasone 
stress fibroblasts are mainly driven 
towards a more aerobic state (shift 
along the y-axis), whereas (c) 
galactose induces a more energetic 
state (shift along the x-axis and y-
axis). The lack of glucose inhibits 
energy provision through glycolysis 
and forces the fibroblasts towards 
meeting their energetic needs by 
OXPHOS. MDD fibroblast lines are 
indicated by white squares, black 
dots represent control fibroblast 
lines; MDD n=16, control n=16. 
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the Complex V of the ETC, the ATP content was determined in the 16 patient and control 
fibroblast cell lines by a luminescence assay.   
As shown in figure 19, there are statistically significant differences in the ATP content 
between MDD patient fibroblasts and control fibroblasts under non-treated conditions. 
Control cells contain more ATP than MDD cells (MDD 59908±11595, CON 73315±12402, 
Wilcoxon matched-pairs signed rank test, * p < 0.05, p = 0.036, mean±SEM). Moreover, 
ATP contents significantly differ between MDD fibroblasts and control fibroblasts after 
DEX stress. Patient cells contain a significantly lower amount of ATP than cells of healthy 
subjects (MDD 52419±10382, CON 58836±11328, Wilcoxon matched-pairs signed rank 
test, ** p < 0.01, p = 0.0052, mean±SEM). These differences could not be detected under 
GAL stress (MDD 89158±15043, CON 99162±14537, Wilcoxon matched-pairs signed rank 
test, p = 0.463, mean±SEM), indicating that only hormonal stress in the cellular model 
leads to an altered provision of ATP in MDD patient cells, but not metabolic stress. The 
differences detected under non-treated conditions correlate with the reduced OCR values 
in various parameters in Seahorse XFp Analyzer measurements in MDD cells.  
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Figure 19 ATP content in fibroblasts. Shown is the ATP content in MDD and control fibroblast lines under non-
treated conditions and after one week of 1 µM DEX or 10 mM GAL stress. Significant differences were found for 
MDD vs. control, non-treated (* p < 0.05, Wilcoxon matched-pairs signed rank test) and DEX (** p < 0.01, compared 
with control, Wilcoxon matched-pairs signed rank test). Bar graphs show normalized mean RLU values ± SEM. 
Dots show the distribution of single RLU values for MDD and control fibroblast lines; MDD n=16, control n=16. 
 
 
 
4.2.3 Bioenergetic properties and mitochondria-related homeostasis in fibroblasts 
The function of the ETC is directly associated with other measurable parameters which 
are linked to crucial functions of the mitochondria and therefore for the viability, survival 
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and homeostasis of the cell. Besides the transport of electrons along the Complexes I-IV, 
a gradient of protons is built across the inner mitochondrial membrane. This gradient is 
decisive for the drive of the ATP synthase and therefore the production of ATP. This 
electro-chemical gradient across the IMM is defined as the MMP. In addition, the 
mitochondria’s function of serving as buffer for the positively charged Ca2+, underlies the 
negative MMP. With the help of fluorescent dyes and live cell imaging those two 
parameters were determined in viable fibroblasts. 
 
4.2.3.1 Mitochondrial Membrane Potential 
 
The MMP in fibroblasts was measured by loading the mitochondria with the cationic dye 
JC-1 (see figure 20). 
 
 
 
Figure 20 Fibroblasts loaded with the cationic dye JC-1. Aggregates of the 
dye fluoresce red, monomers fluoresce green. Scale bar indicates 20 µM. 
 
Depending on the MMP, the dye fluoresces red or green. The ratio between the two signals 
is directly associated with the MMP. Higher red/green ratios indicate a more negative 
MMP. 
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Figure 21 Mitochondrial membrane potential of fibroblasts. (a) Shown are the red/green ratios of MDD and control 
fibroblast lines under non-treated conditions and after one week of 1 µM DEX or 10 mM GAL stress. Significant 
differences were found for MDD vs. control, non-treated (* p < 0.05, compared with control, Student’s t-test, paired, 
two-tailed). Bar graphs show mean red/green ratios ± SEM, MDD n=16, control n=16). Dots show the distribution 
of single red/green values for MDD and control fibroblast lines under non-treated conditions and after one week of 
1 µM DEX or 10 mM GAL stress; MDD n=16, control n=16. b-d Graphs show the pairwise red/green ratios for each 
MDD and control fibroblast line under (b) non-treated conditions and (c) after one week of 1 µM DEX stress or (d) 
10 mM GAL stress. 
 
In fibroblasts, there are detectable significant differences in the MMP between MDD cells 
and control cells (figure 21 a). MDD cells under non-treated conditions show a higher 
red/green ratio suggesting that the MMP is more negative in MDD cells than in control 
cells (MDD 1.40±0.0008, CON 1.35±0.0008, Student’s t-test, paired, two-tailed, ** p < 0.01, 
p = 0.419, mean±SEM). Considering the results of the respiratory experiments, where 
MDD cells show a lower OCR and the fact that MDD contain less ATP, it might be assumed 
that the ATP synthase itself is less active in MDD cells. If the ATP synthase is less active, 
the MMP is not degraded by a reflux of H+ into the mitochondrion as much as in control 
fibroblasts and therefore MDD fibroblasts harbor lower ATP levels compared to healthy 
control cells under non-treated conditions. 
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These alterations are not present under both stress conditions (DEX, MDD 1.46±0.006, 
CON 1.42±0.006, Student’s t-test, paired, two-tailed, p = 0.1874; GAL, MDD 1.46±0.008, 
CON 1.42±0.009, Student’s t-test, paired, two-tailed, p = 0.2443; mean±SEM, figure 21 a). 
Figure 21 a also depicts that the single values within the groups show only little variation, 
also indicated by the small error bars. When comparing the individual pairs, the difference 
between the MDD cells and the control cells vary from pair to pair (figure 21 c-d). Some 
of the gender- and age-matched cell line pairs show bigger differences in the MMP, 
whereas other paired cell lines display smallest or almost no differences in their MMP.  
 
4.2.3.2 Calcium Homeostasis 
 
The capability of mitochondria to store Ca2+ and to serve as a buffer for the important 
second messenger molecule is dependent on the MMP. Cytosolic Ca2+ concentrations were 
assessed by loading viable fibroblasts with the ratiometric dye Fura-2/AM (‘’Fura-2’’). 
The two excitation spectra of Fura-2 in a Ca2+ -bound (380 nm) or Ca2+-free (340 nm) state 
are directly related to the cytosolic amount of Ca2+. The ratio between the emission 340 
nm/380 nm reflect the Ca2+ homeostasis in the cell. High 340 nm/380 nm ratios indicate 
higher Ca2+ concentrations in the cytosol. 
 
Overall, there are no statistically significant differences between cells derived from 
depressed patients and healthy controls in their Ca2+ homeostasis (figure 22 a). The 
340 nm/380 nm ratio, which reflects the Ca2+ amount in the cytosol of the cell, is roughly 
the same und MDD cells and control cells (MDD 0.67±0.013, CON 0.67±0.009, Wilcoxon 
matched-pairs signed rank test, p = 0.4954, mean±SEM). Measurements after one week of 
stress did not result in any statistically significant differences either (DEX, MDD 
0.64±0.005, CON 0.64±0.006 Student’s t-test, paired, two-tailed, p = 0.2285; GAL, MDD 
0.62±0.005, CON 0.62±0.006 Student’s t-test, paired, two-tailed, p = 0.6648; mean±SEM). 
Figure 22 a also depicts that the values within one group do not vary strongly. 
Nonetheless, in some pairs there are bigger intra-pair-individual differences than in other 
pairs. These pairwise comparisons are shown in figure 22 (b-d). It is obvious that pairs 
with higher differences in the Fura-2 ratio do not show these high differences after one 
week of hormonal or metabolic stress. Interestingly, these effects were evened out after 
the application of the stress protocol. 
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Figure 22 Cytosolic Ca2+ homeostasis in fibroblasts. (a) Shown are the 340nm/380nm ratios of MDD and control 
fibroblast lines under non-treated conditions and after one week of 1 µM DEX or 10 mM GAL stress. No significant 
differences were found. Bar graphs show mean 340nm/380nm ratios ± SEM. Dots show the distribution of single 
340 nm/380 nm values for MDD and control fibroblast lines under non-treated conditions and after one week of 
1 µM DEX or 10 mM GAL stress; MDD n=16, control n=16. b-d Graphs show the pairwise 340 nm/380 nm ratios 
for each MDD and control fibroblast line under (b) non-treated conditions and (c) after one week of 1 µM DEX stress 
or (d) 10 mM GAL stress. 
 
 
4. 3 Mitochondrial content: mtDNA copy number in fibroblasts 
In the present study, it could be shown that there are deficiencies in respiratory 
parameters. Additionally, there are differences in the ATP production and the MMP. In the 
literature it has been shown that a reduced energy metabolism is correlated with reduced 
number in mtDNA, whereas higher mtNDA copy number is associated with a lower level 
of depression (Kim et al. 2001). MtDNA replication does not coincide with the cell cycle 
and occurs independently of nuclear DNA replication (Clayton and Bogenhagen 1977). 
Consequently, the mtDNA copy number was determined in relation to the diploid nuclear 
genome in 16 MDD and control fibroblast cell lines. 
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Figure 23 MtDNA copy number in 16 MDD and patient fibroblast cell lines. Shown are the mtDNA copy numbers 
per nDNA of MDD and control fibroblast lines. No significant differences were found. Bar graph show mean mtDNA 
copy number ± SEM. Dots show the single values of mtDNA copy numbers for MDD and control fibroblast lines; 
MDD n=16, control n=16. 
 
As depicted in figure 23, there are no significant differences in the mtDNA copy number 
when MDD and control cell lines are compared (MDD 654±28.04, CON 636±31.68, 
Student’s t-test, paired, two-tailed, p = 0.6540, mean±SEM).  
 
MtDNA copy numbers are, besides the telomere length, part of the ‘’biological clock’’ and  
studies prove that there are significant correlations between mtDNA copy number and 
chronological age (Fries et al. 2017; Mengel-From et al. 2014). In this case we cannot 
detect a correlation between age and mtDNA copy number (Linear Regression Analysis, 
R2 = 0.01742, p = 0.4714). Single values of the mtDNA copy numbers can be taken from 
Table 35 (see Appendix), the age of MDD patients and controls are listed in Table 16. 
 
 
 
4.4 Successful reprogramming of fibroblasts into iPSCs and induction of NPCs 
4.4.1 Cultivation and reprogramming of human dermal fibroblasts 
 
A few days after taking the skin biopsies and cultivation of the skin pieces, primary human 
dermal fibroblasts were growing out of the skin piece. Every cell line could be successfully 
cultivated and cryo-stored. Early passages of the primary fibroblast lines were 
successfully reprogrammed in to iPSCs. By episomal (Epi 5) reprogramming with the 
Yamanka factors stem cell formation was observed after 21-33 days (Takahashi and 
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Yamanaka 2006). Stem cell colonies were successfully isolated and cultivated. With 
immunocytochemistry, staining, markers for pluripotency were detected and labelled.  
 
 
Figure 24 Fibroblasts in cell culture. (left) Shown is a piece of skin with primary human dermal fibroblasts  
growing out. 10X magnification. (right) Primary Human dermal fibroblasts in culture. 40X magnification. 
 
 
 
Figure 25 Reprogramming and iPSC clone separation. (left) iPSC clone formation after 21 days of episomaly 
induced reprogramming of primary human fibroblasts. 40X magnification. (right) selected iPSC clone in culture. 
40X magnification. 
 
4.4.2 Quality control for pluripotency  
The quality control of the iPSCs was conducted by a collaborating laboratory (Prof. Dr. 
Riemenschneider. Neuropathologogy, University Hospital of Regensburg, Regensburg, 
Germany). By PluriTest analysis the first 8 patient and 7 control cell lines were examined 
(Schulze et al., 2016). For 8 of the 15 iPSC lines pluripotency could be confirmed. One 
probe is still pending. The 7 cell lines are close to threshold values. Most likely, the cell 
lines did not pass the PluriTest not because of a lack of pluripotency, but most likely 
10x 
40x 40x 
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because improper iPSC sample collecting with insufficient cleaning of iPSCs colonies and 
therefore fibroblast contamination. 
 
 
Table 22 Results of the PluriTest for pluripotency of iPSC lines. 
Cell line result remarks 
CON2 not pluripotent threshold for pluripotency: 1424, reached value: 1277.0 
CON3 not pluripotent threshold for pluripotency: 1424, reached value 1330.2 
CON4 pluripotent --- 
CON5 pluripotent --- 
CON6 not pluripotent threshold for pluripotency: 1424, reached value 1330.2 
CON7 pluripotent --- 
CON8 pluripotent --- 
MDD1 not pluripotent threshold for pluripotency: 1424, reached value: 1358.5 
MDD2 not pluripotent threshold for pluripotency: 1424, reached value: 1336.6 
MDD3 not pluripotent threshold for pluripotency: 1424, reached value: 1306.5 
MDD4 pluripotent --- 
MDD5 pluripotent --- 
MDD6 pluripotent --- 
MDD7 pluripotent --- 
MDD8 not pluripotent threshold for pluripotency: 1424, reached value: 1404.9  
 
 
4.4.3 Differentiation of neural progenitor cells 
For each iPSC cell line one clone was used to obtain NPCs. Neural induction from iPSC cells 
took 7 days to transform iPSC colonies to early neural progenitor cells. 
NPCs were passaged until p5 in order to reach a higher maturity. Then they were stained 
for neural progenitor markers PAX6 and SOX2 (figure 26). Positive staining for a 
percentage higher than 70% is considered as successful differentiation. Table 23 shows 
that all the differentiated cell lines are > 70% positive for both markers and the 
differentiation was successful. 
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Figure 26 Immunostaining of NPC line MDD4. Staining against (top left) SOX2 (green, 488 rat), (top right) 
PAX6 (red, Cy3) and (bottom left) nuclei (blue). (bottom right) merge picture. Scale bar indicates 20 µm. 
 
 
Table 23 Percentage of PAX6/SOX2 positively stained NPCs 
cell line clone PAX6-positiv (%) SOX2-positiv (%) 
CON1 k 6 87.61 86.00 
MDD1 k 4 90.81 96.25 
CON2 k 12 90,67 89.96 
MDD2 k 12 82.22 85.35 
CON3 k 2 84.64 85.60 
MDD3 k 5 91.73 91.41 
CON4 k 4 86.44 90.76 
MDD4 k 12 84.31 86.94 
CON5 k 1 90.43 93.01 
MDD5 k 4 87.76 89.58 
CON6 k 17 93.14 92.85 
MDD6 k 13 91.78 89.16 
CON7 k 13 91.71 91.71 
MDD7 k 6 89.12 90.38 
CON8 k 2 88.56 89.67 
MDD8 k 13 88.26 90.16 
CON12 k 5 90.67 87.93 
MDD12 k 4 75.34 77.89 
 
 
 
4.5 Alterations of the mitochondrial metabolism in cells of the CNS: Neural 
progenitor cells depict changes in energy supply 
 
Despite that fact that fibroblasts are a suitable model to investigate mitochondria 
function, since differences in the OXPHOS, MMP could be determined in this study and by 
others (Garbett et al. 2015; Karabatsiakis et al. 2014), neural cells are of large interest. 
MDD is a disease of the body and the brain and therefore we extended our studies to 
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investigate mitochondrial function in neural cells. Moreover, the NPCs depend on 
glycolysis to a higher extent when compared to fibroblasts. NPCs were exposed to 
hormonal (DEX) stress, but not to metabolic stress induced by galactose, since NPCs still 
mainly rely on glycolysis like iPSCs and do not survive without glucose over one week 
(Lorenz et al. 2017). 
NPCs are an attractive cellular model since they are an intermediate state between iPSCs 
and neurons and could hint at the impact of mitochondrial dysfunction in the neural 
development (Mlody et al. 2016; Zheng et al. 2016). The developing brain is highly 
dynamic and dependent on proper energetic supply (Edmond 1992). Deficiencies in 
energy supply could therefore influence neuron growth and renewal. 
 
4.5.1 Mito Stress Test: ETC and glycolysis 
4.5.1.1 Respiration of NPCs 
Differentiated NPCs were examined pairwise with the Mito Stress Test protocol in the 
Seahorse Flux XFp Flux Analyzer. After the serial application of four inhibitors of the ETC 
– Oligomycin, FCCP and Rotenone/Antimycin A – the respiratory parameters, namely the 
basal and maximal respiration, the non-mitochondrial respiration, the proton leak, the 
ATP-related oxygen consumption and the spare respiratory capacity were determined.  
Under normal conditions, NPCs from patients exhibit a significantly lower basal 
respiration compared to NPCs from controls (MDD 88.49±3.42, CON 103.72, Student’s t-
test, paired, two-tailed, ** p > 0.01, p = 0.0098, mean±SEM, figure 27 a). 
However, when the NPCs undergo one week of hormonal stress, the differences in the 
basal respiration are repealed. There are no significant differences between MDD and 
controls after DEX stress in basal respiration (MDD 94.53±5.94, CON 107.26±6.49, 
Student’s t-test, paired, two-tailed, * p > 0.05, p = 0.0658, mean±SEM, figure 27 a). NPCs 
exhibit in comparison to fibroblasts a lower rise in OCR after the application of FCCP. 
Whereas fibroblasts can double their OCR, the maximal respiration of NPCs is only about 
one third higher compared to the NPCs basal respiration. The main source of energy of 
NPCs is not OXPHOS but glycolysis which results in lower maximal respiratory abilities.  
The maximal respiration of MDD NPCs and controls NPCs does not differ under non-
treated conditions (MDD 114.94±5.55, CON 131.15±11.54, Student’s t-test, paired, two-
tailed, p = 0.1540, mean±SEM, figure 27 b) neither after DEX stress (MDD 114.61±9.84, 
CON 121.34±2.96, Student’s t-test, paired, two-tailed, p = 0.4294, mean±SEM, figure 27 b). 
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Closely related to the maximal and the basal respiration, is the spare respiratory capacity. 
The spare respiratory capacity is important for the cells’ survival in case of an energetic 
challenge and is a measure for the cell’s energetic reserves. In general, NPCs possess a 
lower spare respiratory capacity than fibroblasts, since OXPHOS is not their main source 
of ATP production. In case of an energetic demand NPCs rely on other energetic sources 
like glycolysis, most probably. In NPCs the spare respiration capacity does not result in 
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Figure 27 Seahorse XFp Flux analyzer results of NPCs. (a) Shown is the basal respiration in NPCs of 
MDD and control cell lines under non-treated conditions and after one week of 1 µM DEX stress. 
Significant differences were found for MDD vs. control, non-treated (** p < 0.01, compared with control, 
Student’s t-test, paired, two-tailed). (b) Shown is the maximal respiration of NPCs of MDD and control 
cell lines under non-treated conditions and after one week of 1 µM DEX stress. No significant differences 
were found. (c) Shown is the spare respiratory capacity in NPCs of MDD and control cell lines under 
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non-treated conditions and after one week of 1 µM DEX stress. No significant differences were found. 
(d) Shown is the non-mitochondrial respiration in NPCs of MDD and control cell lines under non-treated 
conditions and after one week 1 µM DEX stress. Significant differences were found for MDD vs. control, 
non-treated (* p < 0.05, compared with control, Wilcoxon matched-pairs signed rank test). (e) Shown is 
the proton leak in NPCs of MDD and control cell lines under non-treated conditions and 1 µM DEX. 
Significant differences were found for MDD vs. control, non-treated (* p < 0.05, compared with control, 
Wilcoxon matched-pairs signed rank test. (g) ATP production in NPCs of MDD and control cell lines 
under non-treated conditions and after one week of 1µM DEX stress. No significant differences were 
found. Bar graphs show normalized mean OCR values + SEM; MDD n=9, control n=9. 
 
any significant differences between patients and controls under normal conditions (MDD 
27.04±1.44, CON 34.81±7.46, Student’s t-test, paired, two-tailed, p = 0.5256, mean±SEM, 
figure 27 c). Likewise, it does not significantly alter between MDD subjects and healthy 
subjects after the cells were exposed to DEX (MDD 20.08±5.59, CON 14.21±10.62, 
Wilcoxon matched-pairs signed rank test, p = 0.4258, mean±SEM, figure 27 c). Another 
parameter that is determined in the Mito Stress Test is the non-mitochondrial OCR. Non-
mitochondrial OCR  has usually been attributed to inefficient mitochondrial electron 
transport, or to other cellular oxidative reactions not linked to energy metabolism (Herst 
et al. 2004).   
NPCs from controls have a significantly higher non-mitochondrial respiration compared 
to MDD patients at normal culturing conditions (MDD 25.54±1.20, CON 30.82±1.81, 
Wilcoxon matched-pairs signed rank test, * p < 0.05, p = 0.0195, mean±SEM, figure 27 d). 
Similar to the observation for the basal respiration, the non-mitochondrial respiration is 
of no significant difference after hormonal stress exposure (25.62±1.52, CON 28.00±1.40, 
Wilcoxon matched-pairs signed rank test, two-tailed, p = 0.2659, mean±SEM, figure 27 d). 
As proton leak depicts the protons that migrate into the matrix without producing ATP, it 
makes the coupling of substrate oxygen and ATP generation incomplete. Proton leak is 
the principal, but not the only, mechanism that incompletely couples substrate oxygen to 
ATP generation (Cheng et al. 2017). In this parameter NPCs from MDD patients 
significantly differ. The proton leak-associated OCR is significantly higher in control cells 
under normal conditions (MDD 16.63±0.79, CON 19.56±1.01, Student’s t-test, paired, two-
tailed, ** p < 0.01, p = 0.0078, mean±SEM, figure 26 e). However, after DEX stress there 
are no significant aberrations between MDD cells and control cells (MDD 16.22±0.70, CON 
21.02±2.96, Student’s t-test, paired, two-tailed, p = 0.0771, mean±SEM, figure 27 e). 
Regarding the ATP-related OCR, there are no differences between MDD NPCs and control 
NPCs, neither under non-treated conditions (MDD 72.55±2.70, CON 82.94±4.77, Student’s 
t-test, paired, two-tailed, p = 0.0537, mean±SEM, figure 27 f) nor after one week of 
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hormonal stress (MDD 75.87±3.83, CON 85.27±4.64, Student’s t-test, paired, two-tailed, 
0.1368m, , mean±SEM, figure 27 f).  
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Figure 28 Mito Stress Test in NPCs. Typical course for OCR values during a stress protocol in the Seahorse XFp 
Flux Analyzer before compound injection and after application of Oligomycin, FCCP and Rotenone/Antimycin A for 
MDD NPCS (white squares) and control NPC cell line (pair #9). Figure (a) depicts the differences in basal and 
maximal respiration, which are erased respectively diminished after (b) one week of 1 µM DEX stress. Characteristic 
is also the lowered rise in maximal respiration – and the resulting reduction in spare respiratory capacity – after 
FCCP injection due to hormonal stress. 
 
4.5.1.2 Energy profile of NPCs 
 
OCR and ECAR can be used to describe the energetic state of NPCs, as well (figure 29). OCR 
in dependence of ECAR values across the Mito Stress Test can describe the energy states 
MDD and controls for the two different conditions.  
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Figure 29 Energy map of NPCs. Mean OCR in dependence of mean ECAR are shown for MDD and control NPCs 
for non-treated conditions and after one week of 1 µM DEX stress. No significant effects of treatment were found. 
Significant differences were found for MDD vs. control for the non-treated condition (* p < 0.05, compared to control, 
ANOVA with repeated measures Greenhouse-Geisser correction) and after one week of 1 µM DEX stress (** p < 
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0.05, compared to control, ANOVA with repeated measures, Greenhouse-Geisser correction). Data are shown as 
mean OCR±SEM vs. mean ECAR±SEM; MDD n=9, control n=9.  
 
The treatment with DEX (MDD OCR 130.74±8.74 vs. CON OCR 148.07±6.19 vs. MDD ECAR 
50.92±2.50 vs. CON ECAR 52.49±3.65, mean±SEM, figure 30 b) compared to non-treated 
(MDD OCR 127.26±4.02 vs. CON OCR 152.46±5.90 vs. MDD ECAR 55.84±2.40 vs. CON 
ECAR 61.55±1.84, mean±SEM, figure 30 a) did not have significantly different effects on 
MDD and control NPCs, since the shift towards a less glycolytic state and more energetic 
state is similar (ANOVA with repeated measures, Greenhouse-Geisser correction, 
F(1,32) = 1.037, p = 0.316, df = 1, figure 29). Overall, the DEX treatment did not alter OCR 
(MDD OCR DEX 130.74±8.74 vs. MDD OCR N 127.26±4.02; CON OCR DEX 148.07±6.19 vs. 
CON OCR N 152.46±5.90) compared to ECAR (MDD ECAR DEX 50.92±2.50 vs. MDD ECAR 
N 55.84±2.40, CON ECAR DEX 52.49±3.65 vs. CON ECAR N 61.55±1.84, mean±SEM) 
significantly different across both groups (ANOVA with repeated measures, Greenhouse-
Geisser correction, F(1,32) = 1.232, p = 0.275). The treatment with DEX did also not have a 
different effect within the groups on the parameters OCR and ECAR (ANOVA with 
repeated measures, Greenhouse-Geisser correction, F(1,32) = 0.101, p = 0.753, df = 1). The 
treatment with the hormonal stressor causes a slight reduction in OXPHOS in control cells 
as well as a drop in glycolytic activity for MDD and control cells. 
However, when comparing the groups themselves, there is a significant difference 
between MDD and control NPCs (ANOVA with repeated measures, Greenhouse-Geisser 
correction, F(1,32) = 10.677, p = 0.003). MDD and control NPCs significantly differ regarding 
their OCR (MDD N 127.26±4.02 vs. CON N 152.46±5.90, MDD DEX 130.74±8.74 vs. CON 
DEX 148.07±6.19) and ECAR (MDD N 55.84±2.40 vs. CON N 61.55±1.84, MDD DEX 
50.92±2.50 vs. CON DEX 52.49±3.65, mean±SEM) values (ANOVA with repeated measures 
Greenhouse-Geisser correction, F(1,32) = 5.343, p = 0.27). The MDD group has significantly 
lower OCR and ECAR values for non-treated as well as for DEX conditions. Conclusively, 
MDD NPCs show a lower overall metabolism compared to control NPCs, under non-
treated conditions and after DEX stress.  
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Figure 30 Energy map for NPCs for the two conditions. OCR values in dependence of the ECAR values are shown 
for (a) non-treated conditions and (b) after one week of 1 µM DEX stress. DEX stress caused predominantly a 
reduction in overall metabolism for both groups, which is indicated by a shift towards more glycolytic (y-axis) state 
and a shift towards more quiescent (x-axis) state. However, this effect is not statistically significant (ANOVA with 
repeated measures, Greenhouse-Geisser correction, p > 0.05). Nevertheless, there are significant differences 
between MDD and control NPC lines, since OCR and ECAR values are lower in MDD NPCs. Significant differences 
were found for both conditions (compared to control group, ANOVA with repeated measures, Greenhouse-Geisser 
correction, p < 0.05). MDD NPC lines are indicated by white squares, black dots represent control NPC lines; MDD 
n=9, control n=9. 
 
 
4.5.2 ATP content 
The main function and the crucial task also of mitochondria in NPCs is to generate ATP 
out of ADP and Pi. In the last step of the ETC the ATP synthase is driven by the proton 
gradient over the membrane that is built up by the previous reactions at the Complexes I-
V. Inasmuch as in this study we have seen differences in the ATP production in fibroblasts 
of MDD patients and controls, the differentiated neural cells were also measured 
separately in their ATP contents. Since NPCs of patients show a lower basal respiration, it 
might be possible that the ETC does not function properly and this could therefore result 
in differences in the drive of the ATP synthase and lower ATP contents. Nevertheless, 
there are overall no differences in the ATP levels of MDD NPCs and control NPC. As 
depicted in the figure below, cells from MDD patients do not harbor a significantly distinct 
amount of ATP compared to cells from healthy subjects (MDD 341064±49780, CON 
324275±47085, Student’s t-test, paired, two-tailed, p = 0.7939, mean±SEM, figure 31). 
DEX stress does also not cause a difference between MDD subjects and healthy controls 
(MDD 362357±65367, CON 369576±57303, Student’s t-test, paired, two-tailed, 
p = 0.8317, mean±SEM, figure 31). Possibly, the defects in basal respiration and hence 
potential deficits of ETC transport function do not have an impact on the overall ATP 
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levels. NPCs are highly reliant on glycolysis and they can assumedly compensate for 
deficits of the ETC.  
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Figure 31 ATP content in NPCs. Shown is the ATP content in MDD and control NPC lines under non-treated 
conditions and after one week of 1 µM DEX stress. No significant differences were found for MDD vs. control NPCs, 
neither for non-treated and 1 µM DEX stress. Bar graphs show normalized mean RLU values ± SEM. Dots show 
the distribution of single RLU values for MDD and control NPC lines under non-treated conditions and after one 
week of 1 µM DEX stress; MDD n=9, control n=9. 
 
4.5.3 Bioenergetics and mitochondria-related homeostasis in NPCs 
 
Besides the assessment of respiratory parameters in neural cells and the determination 
of the ATP content, the nine differentiated cell lines derived from MDD patients and 
control were observed with the help of fluorescent dyes in order to determine the MMP 
and the cytosolic Ca2+ homeostasis. Since the NPCs from MDD patients exhibited lowered 
OCR values in respiratory parameters, the MMP and the Ca2+ homeostasis, respectively 
the Ca2+ buffer function of the mitochondria, might be also affected. The NPCs are likely to 
show changes in other mitochondria-related properties. 
 
4.5.3.1 Mitochondrial Membrane Potential 
JC-1 measurements in nine NPC cell lines resulted in significant differences. NPCs derived 
from controls show a higher JC-1 red/green ratio compared to NPCs from MDD patients 
(MDD 1.70±0.065, CON 1.84±0.092, Student’s t-test, paired, two-tailed, * p < 0.05, 
p = 0.0286, mean±SEM, figure 32 a).  Higher red/green ratios indicate a lower – more 
negative – MMP. After one week of DEX stress, MDD and control cell lines do not exhibit 
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any significant differences in their MMP (MDD 1.96±0.079, CON 2.04±0.128, Student’s t-
test, paired, two-tailed, p = 0.1843, mean±SEM, Figure 32 a). These observations might be 
related to the change of the ETC function in MDD NPCs. There is a low variance in the 
single values of the JC-1 ratios for all groups, also indicated by small error bars. As figures 
32 b and c show, seven of the nine MDD cell lines show a lower MMP than the control cell 
lines as well as after DEX stress the majority of MDD cells exhibits a lower MMP. However, 
depending on the pair, the differences in MMP vary in size.  
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Figure 32 Mitochondrial membrane potential measurements of NPCs. Shown are the red/green ratios of MDD and 
control NPC lines under non-treated conditions and after one week of 1 µM DEX stress. Significant differences were 
found for MDD vs. control, non-treated (* p < 0.05, compared with control, Student’s t-test, paired, two-tailed). Bar 
graphs show mean red/green ratios ± SEM. Dots show the distribution of single red/green values for MDD and 
control NPC lines under non-treated conditions and after one week of 1 µM DEX stress; MDD n=9, control n=9. b-
c Graphs show the pairwise red/green ratios for each MDD and control NPC line under (b) non-treated conditions, 
(c) after one week of 1 µM DEX. 
 
 
4.5.3.2 Cytosolic Ca2+ homeostasis 
 
Changes in the MMP are closely related to changes in the Ca2+ homeostasis in the cell. 
Therefore, in this study the cytosolic Ca2+ homeostasis was examined with the fluorescent 
dye Fura-2 in nine paired NPC cell lines. Higher Fura-2 ratios are directly related to higher 
amounts of cytosolic Ca2+. Overall, the measurement of Fura-2 ratios did not result in any 
significant differences in NPCs. Statistically, there is no difference between MDD patients 
cell lines compared to the control cell line (non-treated, MDD 0.62±0.01, CON 0.60±0.01, 
Student’s t-test, paired, two-tailed, p = 0.0705; DEX, MDD 0.62±0.01, CON 0.061±0.00, 
Student’s t-test, paired, two-tailed, p = 0.1977; mean±SEM, figure 33 a). Generally, there 
is a low variation in the values in each group, also indicated by small error bars. Despite 
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the fact that MDD patients show a slightly higher Fura-2 ratio for both conditions, the 
values of each pair are of individual differences (figure 33 b-c). 
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Figure 33 Cytosolic Ca2+ homeostasis in NPCs. Shown are the 340 nm/380 nm ratios of MDD and control NPC 
lines under non-treated conditions and after one week of 1 µM DEX stress. No significant differences were found. 
Bar graphs show mean 340 nm/380 nm ratios ± SEM. Dots show the distribution of single 340 nm/380 nm values 
for MDD and control NPC lines under non-treated conditions and after one week of 1 µM DEX stress; MDD n=9, 
control n=9. b-c Graphs show the pairwise 340 nm/380 nm ratios for each MDD and control NPC line under (b) 
non-treated conditions and (c) after one week of 1 µM DEX stress. 
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5 Discussion 
5.1 Fibroblasts from MDD patients show lower respiratory rates and altered 
bioenergetic functions 
In the present study, it could be demonstrated that there are differences in the 
mitochondria-related functions in MDD fibroblasts compared to the fibroblasts from 
gender- and age-matched healthy controls. Fibroblasts from MDD patients show lower 
OCR values for basal and maximal respiration, the spare respiratory capacity, the non-
mitochondrial respiration and the ATP-turnover related respiration. Lower basal 
respiration and a reduced ATP-related OCR rate could either be a consequence of a 
diminished activity of the mitochondrial respiratory chain or a restricted substrate or 
enzyme availability. In case of a restricted availability of the substrates glucose or fatty 
acids or the improper functioning of enzymes in their metabolic breakdown (e.g. the 
hexokinase or the Acyl-CoA Dehydrogenase), the availability of the reduction equivalents 
NADH/H+ and FADH2 is limited.  Moreover, those reduction equivalents have to be 
shuttled into the mitochondrion, which also can be a limiting factor for the function of the 
ETC (Leverve 2007). The levels of reduction equivalents in MDD and control cells were 
not determined in this study. In order to draw a conclusion if the reduced respiration is 
because of a reduced presence of NADH/H+ or FADH2 further measurements are needed. 
However, a lower basal respiration can also result from a reduced function of the ETC 
itself, meaning that the Complexes I – IV might exhibit a lower activity in MDD fibroblasts.  
The inhibition of Complex I by rotenone was shown to cause an inhibition of Complex II 
since the TCA cycle stops succinate production when NADH/H+ is not oxidized since there 
are no succinate sources in the cytosol (Steinlechner-Maran et al. 1997). Complex I 
produces most of the superoxide. A defect of Complex I activity, therefore, can be 
considered as a potential cause for altered ROS levels (Paradies et al. 2004). It cannot be 
excluded that the reduced respiration in MDD fibroblasts origins from a reduced 
mitochondrial mass. An estimation of the mitochondrial content in permeabilized PBMCs 
of acutely depressed patients resulted in increased levels and Karabatsiakis et al. 
therefore concluded the lowered respiration is actually attributable to a lower ETC 
function (Karabatsiakis et al. 2014). However, for this study, the mitochondrial content 
definition by CS activity – as is was determined in the study of Karabatisakis et al. – is 
remaining to be done. 
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Non-mitochondrial oxygen consumption is observed at low levels in a variety of cells and 
tissues. This has been linked to an inefficient ETC or to other cellular oxidative reactions 
which are not linked to energy metabolism (Herst et al. 2004). MDD fibroblasts exhibit a 
lower non-mitochondrial respiration compared to control fibroblasts, which could be 
either point at a reduced activity of the ETC or a generally decreased metabolism. 
Moreover, the reduced maximal uncoupled respiration and the lower spare respiratory 
capacity indicate that the fibroblasts of MDD patients exhibit a reduced capacity of 
mitochondrial respiration. This decreased capacity might result in a lack of energy in 
times of higher energy demand (Buttgereit, Burmester, and Brand 2000).  
Similar observations to those in the present study were made in PBMCs of acutely 
depressed patients. Karabatsiakis et al. also observed a reduction in routine respiration, 
ATP turnover-related respiration and uncoupling efficiency (Karabatsiakis et al. 2014). 
These findings are in line with those from Hroudová et al. . They revealed that the 
physiological respiratory rate and the maximal capacity of the ETC are significantly 
decreased in intact blood platelets of patients with a current depressive episode – 
regardless of a partial or complete remission of the mild to severe depressive symptoms 
(Hroudová et al. 2013). Another study demonstrated that muscle cells of depressed 
patients show an impaired activity of Complex I+III and II+III. They also discovered a 
significant decreases of mitochondrial ATP production rates (Gardner et al. 2003). In the 
present study significantly lower ATP levels in MDD fibroblasts could also be measured. 
This finding is in line with the overall decreased respiration of MDD fibroblasts and the 
reduced ATP-related turnover in particular. 
The electron flow at each complex of the ETC is used to pump protons into the IMS and 
the MMP is build up over the IMM. The flux of protons down their electrochemical 
gradient trough the ATP synthase to generate ATP (Spinelli and Haigis 2018). The MMP is 
more negative in MDD fibroblasts whereas they harbor lower ATP levels. This observation 
might be related to a reduced function of the ATP synthase and therefore a preserved 
proton gradient causing the more negative MMP. The general assumption is that the 
electrochemical gradient regulates the activity of the ETC complexes. At high potentials 
further proton pumping is inhibited. A decrease of the MMP due to proton utilization, e.g. 
by the ATP synthase, allows the ETC to rebuild the MMP. Thus, mitochondria in intact cells 
respire between the extreme energetic states, state 3 in the presence of ADP and state 4 
when ADP has been converted into ATP (Hüttemann et al. 2008). Studies of fibroblasts 
with primary defects in mitochondrial ATP synthase show that the MMP at state 4 is 
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normal, but ADP-induced discharge of the MMP is impaired as ATP synthesis at state 3 is 
decreased. Increased MMP and low ATP synthesis is also found when the ATP synthase 
content is diminished by altered biogenesis of the enzyme complex (Vojtíšková et al. 
2004). 
Although the ER is considered to be the main intracellular Ca2+ store, mitochondria 
essentially contribute to the cellular Ca2+ homeostasis. Mitochondria are able to 
accumulate Ca2+ in an energy-dependent way and they release Ca2+ through antiporters. 
Mitochondrial key functions – in particular the matrix dehydrogenases - are strongly 
influenced by the cytosolic Ca2+ level (Denton 2009). Cytosolic Ca2+ also influences the 
activity of other mitochondrial enzymes at the IMM such as the glycerophosphate 
dehydrogenase or the malate-aspartate shuttle (Satrústegui, Pardo, and Del Arco 2007). 
The examination of cytosolic Ca2+ in MDD fibroblasts and fibroblasts from controls did not 
reveal any significant differences. Mitochondrial Ca2+ concentrations were not assessed 
in the present study. However, the more negative MMP in MDD fibroblasts could cause a 
higher uptake of Ca2+ into the mitochondrion. Exceeded Ca2+ uptake by mitochondria 
triggers a bioenergetic failure of the organelle through the opening of the permeability 
transition pore, the release of Cyt c and other pro-apoptotic factors which cause cellular 
death by apoptosis or necrosis (Kroemer, Galluzzi, and Brenner 2007). Whether the more 
negative MMP in MDD fibroblasts also results in higher mitochondrial Ca2+ remains 
elusive in this case and will be part of further measurements. 
 
 
5.2 Enhanced metabolism in fibroblasts due to hormonal and metabolic 
stressors 
Besides the basal, non-treated state, the fibroblasts were investigated after one week of 
1 µM DEX stress or after one week of 10 mM GAL stress. 
Glucocorticoid hormones play an important role in times of stress by regulating salt and 
water metabolism, blood pressure, immune function, and carbohydrate, protein and fat 
metabolism (Schäcke, Döcke, and Asadullah 2002). However, chronic glucocorticoid 
treatment induces side effects, including insulin resistance, a catabolic effect on the 
skeletal muscle and an increased risk of osteoporosis (Schäcke, Döcke, and Asadullah 
2002). Chronic exposure to either endogenously released or synthetic GC is related to 
numerous physical diseases, but also mental disorders (Björntorp and Rosmond 2000; 
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Pufall 2015b; Steckler, Holsboer, and Reul 1999; Strüber, Strüber, and Roth 2014b). Long-
term GC presence causes ETC dysfunction, increased ROS, mitochondrial abnormalities, 
apoptosis and cell death (Manoli et al. 2007). 
In this study, the overall analysis of the Mito Stress Test by ANOVA with repeated 
measures revealed a significant enhancement of OXPHOS, but not glycolysis, due to DEX 
exposure. DEX stress induced in both groups – MDD and controls – a rise of the OCR in all 
parameters of the Mito Stress Test. The differences in the OCR detected in the Mito Stress 
Test between MDD fibroblasts and control fibroblasts for the non-treated state could not 
be measured after the DEX condition. It is known that chronic injection of glucocorticoids 
over 3 to 7 days decreases the rate of oxygen consumption and lowers phosphate/oxygen-
ratio (the ATP produced per oxygen atom reduced by the respiratory chain) of liver 
mitochondria, but not in mitochondria from skeletal muscle (Bullock et al. 1972; Kerppola 
1959; Kimberg, Loud, and Wiener 1968; Peter, Verhaag, and Worsfold 1970).  
A 48 h treatment with 1 µM of dexamethasone in adipocytes caused an impaired insulin-
induced glucose uptake and a mitochondrial dysfunction. The mitochondrial dysfunction 
was supported by decreased intracellular ATP and MMP, increased intracellular and 
mitochondrial ROS and mtDNA damage. Changes in the mitochondrial dynamics and 
biogenesis were suggested by decreased Drp1, increased Mfn2, and decreased PGC-1α, 
NRF1, and TFam levels (Guangxiang et al. 2019). Although the application of DEX resulted 
in a higher activity of the ETC and OXPHOS, MDD and control fibroblasts exhibit slightly 
lower ATP levels. The exposure of fibroblasts to 1µM DEX seems to have rather adverse 
effects on the energy supply. MDD fibroblasts exhibit significantly lower ATP levels 
compared to control fibroblasts. The enhancement of the ETC machinery through DEX 
might have caused, that the MMP is not significantly different between MDD fibroblasts 
and controls. Yet, MDD fibroblasts exhibit significantly lower ATP levels, suggesting a 
restricted substrate or enzyme availability also under hormonal exposure.  
Besides hormonal stress induced by DEX, metabolic stress was induced by 10 mM 
galactose instead of glucose in the culture medium. The production of pyruvate  
via glycolytic metabolism yields 2 net ATP, whereas the production via glycolytic 
metabolism of galactose yields no net ATP. Therefore, the cells are forced to have an 
increased reliance on OXPHOS for their energy supply (Marroquin et al. 2007; Robinson 
et al. 1992; Rossignol et al. 2004). Different types of cells, e.g. cancer cells or primary 
fibroblasts, grown in a medium in which glucose is replaced with galactose show a 
significantly increased OCR compared to cells grown in medium containing a high 
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concentration of glucose. Cells grown in galactose exhibit a more aerobic state due to a 
diminished ATP production via anaerobic glycolysis (Bustamante and Pedersen 1977). It 
is also suggested that galactose modulated mitochondrial structure and the oxidative 
capacity is risen by increased OXPHOS protein expression and enzymatic activities 
(Rossignol et al. 2004). The study by Robinson et al. showed that primary skin fibroblasts 
isolated from patients with mitochondrial deficiency including cytochrome oxidase 
deficiency, complex I deficiency, pyruvate dehydrogenase complex deficiency or with 
multiple respiratory chain defects, were not able to survive when cultured in a galactose-
based medium (Robinson et al. 1992). Aguer et al. assessed the mitochondrial respiration 
in human primary muscle cells after 7 day and acute (24 h) 10 mM galactose incubation 
and they discovered higher OCR rates after chronic but not after acute exposure. 
Moreover they confirmed a lower aerobic metabolism proofed by a diminished 
generation of lactate (Aguer et al. 2011). 
In the present study of MDD fibroblasts and control fibroblasts the GAL treatment 
resulted in an overall significant heightened metabolism compared to the non-treated 
state. However, not only OCR was fueled, but also ECAR. Although the acidification rate is 
widely used to describe glycolytic events, glycolysis is not the sole contributor to the 
production of H+. Extracellular acid produced by cells is derived from both lactate, 
produced by anaerobic glycolysis, and CO2, produced in the citric acid cycle during 
respiration. The export of CO2, the hydration to H2CO3 and the dissociation to HCO3- + H+ 
is the reason for respiratory acidification (Mookerjee et al. 2015). This phenomenon 
might explain the elevated ECAR levels in fibroblasts despite of glucose deprivation. The 
higher respiratory rate causes a higher extracellular acidification.  
The respiratory parameters of the Mito Stress test do not result in significant differences 
between patients and controls due to GAL exposure, except the non-mitochondrial 
respiration. The ATP levels are higher for both groups compared to non-treated 
conditions and there are no significant differences between MDD fibroblasts and controls. 
The measurements of MMP and cytosolic Ca2+ did also not result in any significant 
differences between MDD and control fibroblasts subsequent to GAL exposure. A study by 
Garbett et al. has shown that metabolic challenges evoked by substitution of glucose with 
GAL or reducing the abundance of lipids in the growth media of fibroblasts from MDD 
patients result in changes of mRNA and miRNA expression. These stress-induced changes 
are suggested to be MDD-related. The impairments in molecular pathways involved in the 
control of metabolism and energy production, cell survival, proliferation and migration 
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were found in MDD fibroblasts due to GAL and reduced-lipid challenges, but not in control 
fibroblasts (Garbett et al. 2015).  
 
 
5.3 Similar mitochondrial densities in MDD and control fibroblasts 
Mitochondrial volume or content is an important quantitative indicator, since the 
mitochondrial mass is dependent on intact mitochondrial dynamics and therefore proper 
mitochondrial bioenergetics (Chen, McCaffery, and Chan 2007; Detmer and Chan 2007). 
The mitochondrial content is most commonly defined by the measurement of the Citrate 
Synthase (CS) activity, the mtDNA copy number, cardiolipin or the activity of the Cyt c 
oxidase (Boushel et al. 2007; Karabatsiakis et al. 2014; Mogensen et al. 2006; Picard, 
Taivassalo, Ritchie, et al. 2011; Ritov, Menshikova, and Kelley 2006). In the present study 
the mitochondrial content was determined by mtDNA copy number. Using this method, 
there are no significant differences in mtDNA copy number between MDD fibroblasts and 
control fibroblasts. This observation suggests that the differences detected in respiratory 
parameters and bioenergetic properties are not due to differences in the mitochondrial 
mass. Hroudová et al. determined mitochondrial content by CS activity in blood platelets. 
Although they did not mention absolute CS values, they reported that after CS 
normalization the significant differences in respiration were sustained (Hroudová et al. 
2013). Other studies report contrary results. The mitochondrial content definition, by the 
analysis of CS activity, in PBMCs from depressed subjects revealed higher densities, 
suggesting that this increase in mitochondrial mass is an attempt of the body to 
compensate for the reduced efficiency in mitochondrial ATP production (Karabatsiakis et 
al. 2014). This finding is in line with a study by Cai et al. . They revealed that the amount 
of mtDNA alters in response to external stress: there was significantly more mtDNA in the 
saliva and blood of people with MDD than in controls. Besides that, chronic stress also 
altered the amount of mtDNA in mouse tissues. The stressed mice also showed a lowered 
mitochondrial respiratory activity (Cai et al. 2015).  
Furthermore, Wang et al. proposed elevated mtDNA copy numbers in MDD as a 
compensatory mechanism for energetic deficiencies (Wang et al. 2017).  
Nonetheless, Larsen et al. published a study, examining the different biomarkers and their 
correlation to cristae surface area determined by TEM. The goal was to evaluate the 
association and validity of CS activity, cardiolipin content, mtDNA, Complex I-V protein 
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content and Complex I-IV activity to muscle mitochondria content and OXPHOS in skeletal 
muscle cells from healthy subjects. Cardiolipin content, followed by CS activity and 
Complex I activity, were the biomarkers exhibiting the strongest association with 
mitochondrial content, whereas mtDNA was supposed to be a possibly less suitable 
method to estimate the mitochondrial content in skeletal muscle cells (Larsen et al. 2012). 
Considering those contrasting findings for mitochondrial mass determination, a future 
quantification of the mitochondrial mass in MDD fibroblasts and controls in terms of 
cardiolipin determination or CS activity measurement is suggested.  
 
 
5.4 Decreased mitochondria-related metabolism in MDD NPCs 
MDD fibroblast and control cell lines were reprogrammed into iPSCs by the ectopic 
overexpression of the transcription factors including Oct3/4, Sox2, Klf4, c-Myc and 
differentiated in to NPCs that express the neural stem cell markers PAX6 and SOX2 
(Takahashi and Yamanaka 2006; Yan et al. 2013). Several studies reported that following 
the reprogramming of iPSCs, the epigenetic memory is inherited from the parental cells 
(Doi et al. 2009; Kim et al. 2010; Lister et al. 2011; Ohi et al. 2011; Polo et al. 2010).  
In the first part of this study, it could be shown that there are detectable bioenergetic 
alterations in the somatic cells. In the second part could be shown that, despite of the 
whole progress of reprogramming to iPSCs and the differentiation process, there are also 
measurable differences in the bioenergetics of mitochondria in NPCs. 
The Mito Stress Test revealed that NPCs from MDD patients exhibit a significantly lower 
basal respiration, a lowered non-mitochondrial respiration and a significantly lower OCR 
for the proton leak under standard culturing conditions. However, MDD NPCs do not 
exhibit a lower maximal respiration as it could be measured for MDD fibroblasts. There 
are also no statistically different levels in the ATP production determined by the 
bioluminescence assay. This observation could be due to the slightly distinct metabolism 
in NPCs compared to fibroblasts. Whereas fibroblasts are highly reliant on OXPHOS, NPCs 
gain a large part of their energy via glycolytic pathways (Lorenz et al. 2017; Zheng et al. 
2016). Therefore, it is suggested that potential deficits in ETC activity – indicated by the 
lowered basal respiration - in MDD NPCs can be compensated by the generation of energy 
through glucose metabolism. In accordance with the lower basal respiration, the MMP in 
MDD NPCs is less negative. 
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The proton circuit across the IMM optimally drives the OXPHOS, where substrate 
oxidation and ADP phosphorylation are coupled. The oxidation of substrates releases 
electrons to NADH or FADH2. These electrons are passed through electron carriers in 
respiratory chain complexes with increasing oxidation potentials. This exergonic 
reactions transports protons from the matrix to the IMS, eventually creating an 
electrochemical gradient and the proton motive force driving the ATP synthase (Alberts 
et al. 2002). However, this proton motive force is incompletely converted into ATP, since 
the coupling is only about 50–80 %. This loss of energy is due to protons that return to 
the matrix independently of ATP synthase (Buttgereit, Burmester, and Brand 2000). The 
proton leak, and also the electron leak, have an impotent impact on mitochondrial 
coupling efficiency and production of reactive oxygen species. The OCR values assigned 
to the proton leak in MDD NPCs are significantly lower compared to those of control NPCs. 
This observation could indicate that the uncoupling in control NPCs is actually less 
efficient. Taken together, these findings point towards a lower substrate or enzyme 
availability in MDD NPCs.  
The cytosolic Ca2+ levels do not significantly alter between MDD and control NPCs. 
However, unlike in fibroblasts, in MDD NPCs there is a trend towards a higher cytosolic 
Ca2+ level. This observation is in accordance with the measurement of a significantly less 
negative MMP in MDD NPCs. Mitochondria have important buffer functions since they 
sequester – due to their negative MMP – large amounts of Ca2+ (Ernster and Schatz 1981). 
Especially in neuronal cells, the cytosolic Ca2+ concentration is critical. Elevated cytosolic 
Ca2+ would stimulate glutamate release which causes an activation of N-methyl-D-
aspartate receptors. This in turn would result in massive Ca2+ influx and cell damage and 
death (Kannurpatti, Joshi, and Joshi 2000). Elevated Ca2+ levels in NPCs due to a 
disturbance of the sequestration of Ca2+ by their mitochondria therefore might induce 
apoptosis and hence this might cause a reduced cellular mass that could give rise to 
neurons or astrocytes, for example. Cytosolic Ca2+ in iN of two MDD patient and control 
pairs of this study were already shown to be significantly altered and will depict an 
important objective in future investigations (Röhrl 2019). 
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5.5 Effects of the synthetic hormonal stressor dexamethasone in NPCs 
GC levels are elevated in neuropsychiatric disorders and it is known that their chronic 
administration causes a loss of memory and impaired logical thinking, disrupted HPA axis 
function and alterations in calcium homeostasis in neurons (Chen et al. 2011; Lajic, 
Nordenström, and Hirvikoski 2011; Young et al. 1999). The effects of a glucocorticoid – 
dexamethasone – were also tested in this cellular model. Besides the evaluation of the 
bioenergetic properties of NPCs under standard culturing-conditions, the cells were 
exposed to a synthetic hormonal stressor for one week. After the NPCs were treated with 
DEX, they do not exhibit any significant differences in the Mito Stress Test. The significant 
differences between MDD NPCs and control NPCs in basal respiration, non-mitochondrial 
respiration or proton leak are not detectable under stressed conditions. After 1 week of 1 
µM DEX stress there are no significant differences in the MMP between control and MDD 
NPCs. One possible explanation could be, that, as the overall analysis of the metabolism 
revealed, MDD NPCs exhibit slightly heightened OCR values consequently to hormonal 
stress. However, DEX did not cause a significant effect on overall metabolism – 
considering OCR and ECAR together – in MDD and control NPCs as it did in fibroblasts. 
However, the analysis of the overall metabolism, respectively OCR in the dependence of 
ECAR, revealed that also MDD NPCs show a significantly lower metabolism under 
standard culturing conditions but also after DEX stress. Generally, the exposure to chronic 
(hormonal) stress is considered to be detrimental to mitochondrial metabolism. The 
adverse effects include a lowered OXPHOS function, disruptions of the MMP and Ca2+ 
homeostasis, damage of mtDNA and elevated ROS levels (Manoli et al. 2007). In this study, 
possibly the exposure of 1 µM DEX for 7 days was too short to induce deficiencies in the 
OXPHOS. Similar to the effects in fibroblasts, NPCs exhibited rather the beneficial effects 
of an acute exposure to stress than the adverse consequences. An important regulator for 
mitochondrial biogenesis is PGC-1α. Balanced levels of this master regulator are crucial 
for driving OXPHOS and energy expenditure (Michael et al. 2001; Wu et al. 2006). PGC-1α 
levels were not determined in the present study. The measurement of PGC-1α by qPCR 
will be considered as a future objective.  
Suwanjan et al. examined the mitochondrial dynamics underlying dexamethasone-
induced toxicity in the human neuroblastoma SH-SY5Y cells. The treatment with DEX for 
24 h of those neuronal cells resulted in a marked decrease in cell proliferation. DEX-
induced neurotoxicity also caused upregulation of mitochondrial fusion. Unlike in the 
present study with NPCs, in the study of Suwanjang et al. a reduced ATP production could 
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be detected due to DEX treatment. Furthermore they reported increased ROS levels 
(Suwanjang et al. 2019). Morin et al. tested the effects of four different glucocorticoids – 
hydrocortisone, triamcinolone, prednisolone and dexamethasone – on isolated rat brain 
mitochondria. The application of 1 µM DEX caused a reduction of respiratory rates due to 
an inhibition of oxidative phosphorylation (state 3 respiration) and of Complex V activity 
and a modification of the proton-fluxes through the mitochondrial inner membrane. 
Moreover, DEX also inhibited the CCCP-induced rise in the OCR in a concentration-
dependent manner. Morin et al. suggested therefore an adverse effect of glucocorticoids 
on brain mitochondria and a limited capacity to increase OCR upon ETC stimulation 
(Morin et al. 2000). Nonetheless, DEX stimulation in NPCs did exhibit neither significantly 
negative nor significantly beneficial effects in the present study. The possibly differential 
effects on mitochondria of iN from MDD and controls remain elusive and will be part of 
further studies.  
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6 Conclusion and future perspectives 
 
The aim of this study was to investigate the association of mitochondrial function and 
underlying pathopsychological mechanisms in MDD. 
This study shows that cells from MDD patients and healthy controls exhibit differences in 
mitochondria-associated functions. In this explorative approach the mitochondrial key 
functions in fibroblasts were assessed and differences between MDD patients and healthy 
controls could actually be demonstrated. Mitochondria in fibroblasts of MDD patients 
appear to have reduced oxidative capacities and therefore a reduced energy availability. 
These alterations in the somatic cells were in line with those from other groups 
(Hroudová et al. 2013; Karabatsiakis et al. 2014). Nonetheless, an indispensable objective 
for the future will be the verification of the mitochondrial mass with a second method. In 
order to know if the respiratory differences origin from a lower density of mitochondria, 
a measurement of the CS activity is suggested 
Moreover, mitophagy is an important aspect with regard to mitochondrial mass. 
Mitophagy, as well as fission and fusion, are the cells’ major mitochondria quality control 
mechanisms and ensure a whole mitochondrial genome turnover and proper 
mitochondrial functioning (Dombi, Mortiboys, and Poulton 2018). The recycling and 
engulfment of mitochondria by acidic lysosomes can be visualized by transfection of cells 
with mt-Rosella, which is a dual-emission biosensor sensitive to pH changes (Sargsyan et 
al. 2015). Therefore, mitophagy is strongly suggested to be assessed also in MDD 
fibroblasts to control for a functional restoring of mitochondria. 
A regulator of mitochondrial dynamics is OPA1 and it is – among many others – one of 
many targets of human sirtuins (SIRT) that coordinate a variety of molecules involved in 
certain aspects of cellular metabolism (Dombi, Mortiboys, and Poulton 2018). SIRT are 
transcription regulators and may act as metabolic sensors, since they are dependent on 
NAD+ levels. NAD+ links transcriptional events and changes in cellular signaling to cellular 
metabolism. NAD+ has a pivotal role in mitochondrial metabolism: NAD+ accepts H- 
equivalents to form reduced NADH, which then provides reducing equivalents to the 
mitochondrial ETC and to fuel OXPHOS (Cantó, Menzies, and Auwerx 2015). Therefore, a 
crucial objective for future investigations is the assessment of NAD+/NADH ratios. The 
determination of NAD+/NADH ratios allow a more detailed statement about the reduction 
equivalent availability and the redox state in MDD cells versus control cells.  
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The redox potential of a cell is widely defined by GSH. The majority of GSH is found in the 
cytosol. However, a small but significant percentage is also found in the mitochondria. 
Mitochondrial GSH is of huge importance protecting the organelle from ROS produced 
during coupled mitochondrial electron transport and OXPHOS (Buttke and Sandstrom 
1994). A lack of antioxidant defenses, e.g. GSH, leads to a generation of high ROS levels, 
which is suggested to act as a signal for the induction of apoptosis (Langer, Jürgensmeier, 
and Bauer 1996).  In the context of the present study, the investigation of GSH levels 
depicts an interesting future approach to determine the capability of scavenging 
superoxide in MDD cells. 
 
To my knowledge, this is the first study to investigate bioenergetics in neural cells derived 
from iPSCs of MDD patients. It could be shown that differences in respiration and the MMP 
in peripheral cells are also present at neuronal cell level, despite the process of 
reprogramming and differentiation. These novel observations highlight the importance of 
further investigations of mitochondria – especially in neurons. Neural cells require in 
comparison to peripheral cells higher amounts of energy: The brain with its high 
metabolic rate consumes 20% of the whole-body oxygen uptake (Vergara et al. 2019). 
Neurons might be even more sensitive to potential improper mitochondrial functioning 
and insufficient energy provision. 
First experiments with iN of selected patient and control pairs showed that neurons from 
MDD patients exhibit altered properties including Ca2+ homeostasis and spontaneous 
activity (Röhrl 2019; Triebelhorn, in preparation). Cytosolic Ca2+ was measured with the 
help of Fura-2. However, mitochondrial Ca2+ levels will also be in focus of future 
investigations. Mitochondrial Ca2+ levels can be assessed by the use of the fluorescent dye 
Rhod-2, for instance. However, synthetic fluorescent indicators targeted to mitochondria 
have blunted responses to repetitive increases in mitochondrial Ca2+ and disrupt 
mitochondrial morphology. Moreover, indicators like Rhod-2 tends to leak out of 
mitochondria over several hours which makes them unsuitable for long-term 
experiments (Nagai et al. 2001).  Ratiometric mt-Pericam though, which is an indicator 
based on a fusion of circularly permuted yellow fluorescent protein and calmodulin, is 
genetically encoded and  allows the measurement of rapid changes in and long-term 
measurements of mitochondrial Ca2+ concentrations (Akimzhanov and Boehning 2011). 
Moreover, first experiments with the treatment of cells with the particular ADs the 
patients received were conducted. Mitochondrial respiration, MMP and Ca2+ homeostasis 
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was assessed after 24 h, 3 days and 7 days of ADs treatment of fibroblasts. MMP and 
cytosolic Ca2+ homeostasis were assessed iN consequently to ADs treatment. It could be 
shown that the ADs have different effects on the MDD patient cells compared to the 
matched control (Röhrl 2019). Since the MDD patients of this study responded to AD 
treatment, the inclusion of non-responder is proposed for future investigation in order to 
gain more detailed insight into potential pathologic changes and the association to 
mitochondrial (dys-)function in MDD. 
However, the importance of respiratory deficiencies and the energy supply in iN of MDD 
patients is unresolved. The effect of stress and the impact of ADs on OXPHOS activity in 
MDD iN remain widely elusive and depict a future direction of research.  
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Table 24 Mean and SEM values for respiratory parameters of fibroblasts 
 
Basal Respiration Maximal Respiration Spare Respiratory 
Capacity 
mean OCR SEM mean OCR SEM mean OCR SEM 
MDD N 16.09 0.88 32.20 2.23 16.11 1.81 
Control N 18.53 0.95 37.01 2.40 18.95 2.29 
MDD DEX 22.96 1.14 48.76 3.88 25.28 3.15 
Control DEX 23.25 1.12 45.03 2.32 27.76 3.92 
MDD GAL 22.31 1.70 57.86 2.64 35.91 3.19 
Control GAL 22.64 1.58 60.04 3.41 37.33 3.65 
 
 
non-mitochondrial 
Respiration 
Proton Leak ATP -related 
Respiration 
mean OCR SEM mean OCR SEM mean OCR SEM 
MDD N 7.90 0.71 2.38 0.20 13.71 0.76 
Control N 9.65 0.91 2.80 0.22 15.72 0.82 
MDD DEX 11.08 0.95 2.94 0.31 19.91 0.90 
Control DEX 11.84 0.79 2.72 0.29 20.52 0.97 
MDD GAL 15.43 1.34 3.99 0.58 18.32 1.26 
Control GAL 18.05 1.60 3.76 0.37 18.88 1.27 
 
 
Table 25 Single values (non-treated) for OCR and ECAR for 16 MDD and control fibroblast lines 
 
N 
 
MDD Control 
Pair OCR ECAR OCAR ECAR 
#1 22.49 18.03 23.45 10.99 
#2 30.03 11.27 31.44 12.65 
#3 29.63 13.82 28.19 12.15 
#4 24,63 10.67 22.91 9.52 
#5 18.01 12.25 19.59 12.54 
#6 26.13 16.30 26.05 16.01 
#7 22.07 10.39 46.04 12.23 
#8 20.75 15.47 32.40 13.46 
#9 25.23 16.86 29.46 8.36 
#10 28.59 10.35 37.79 15.66 
#11 26.74 24.38 30.16 16.53 
#12 25,97 14.54 25.92 9.76 
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#13 22,69 9.84 30.25 9.37 
#14 30.48 9.16 33.19 20.23 
#15 17.96 11.41 20.76 12.98 
#16 21.41 14.07 31.49 12.29 
 
 
Table 26 Single values (dexamethasone) for OCR and ECAR of 16 MDD patients and control fibroblast lines 
 
Dexamethasone 
 
MDD Control 
Pair OCR ECAR OCR ECAR 
#1 53.55 17.93 58.86 14.18 
#2 37.21 5.89 64.30 20.29 
#3 45.31 7.38 40.41 7.48 
#4 34.90 19.33 33.07 10.53 
#5 23.23 8.33 28.63 9.59 
#6 46.83 15.69 43.97 11.81 
#7 24.39 8.07 42.41 10.24 
#8 28.61 7.51 48.86 10.24 
#9 37.49 11.52 43.16 12.29 
#10 36.73 13.79 42.97 9.53 
#11 35.87 10.55 42.57 13.05 
#12 44.58 15.01 49.54 16.93 
#13 47.74 1.69 48.17 8.60 
#14 18.94 3.29 20.30 5.57 
#15 40.94 14.80 40.03 13.68 
#16 79.48 11.08 50.68 5.46 
 
 
Table 27 Single values (galactose) for OCR and ECAR of 16 MDD patients and control fibroblast lines 
 
Galactose 
 
MDD Control 
Pair OCR ECAR OCR ECAR 
#1 29.74 15.76 30.53 15.39 
#2 30.36 17.90 39.13 22.72 
#3 46.32 18.51 41.86 16.67 
#4 30.50 12.11 29.84 8.79 
#5 41.26 15.28 28.96 17.27 
#6 39.81 12.32 40.85 13.87 
#7 32.15 12.02 40.54 16.82 
#8 36.66 13.14 43.41 13.89 
#9 59.61 18.47 63.51 19.12 
#10 89.13 43.59 72.84 26.04 
#11 52.29 15.59 59.37 16.09 
#12 68.26 31.40 69.54 18.35 
#13 56.03 17.51 62.29 13.05 
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#14 57.89 11.30 51.49 8.50 
#15 82.35 37.22 73.74 21.74 
#16 42.71 18.54 47.60 10.63 
 
 
Table 28 Mean and SEM values for ATP measurements of fibroblast lines for 16 MDD patient and control 
pairs 
 
mean (RLU) SEM 
MDD N 59908 11595 
Control N 73315 12402 
MDD DEX 52419 10382 
Control DEX 58836 11328 
MDD GAL 89158 15043 
Control GAL 99162 14537 
 
Table 29 Single RLU values of 16 MDD patient and control pairs of fibroblast cell lines 
Pair MDD N Control N MDD DEX Control DEX MDD GAL Control GAL 
#1 28725 31958 6698 8282 74970 35427 
#2 40717 65304 33293 33580 38739 47343 
#3 44159 35897 17237 23195 44297 32185 
#4 30804 42182 32253 54649 13624 116515 
#5 21119 37008 26295 34799 57752 79691 
#6 44089 110166 19703 29094 47092 118424 
#7 22327 42185 13633 21345 110430 107092 
#8 17573 87942 32355 9829 43236 26867 
#9 51614 33690 31646 31861 53646 47419 
#10 134620 149176 129238 143042 193662 193708 
#11 41377 43084 38246 39944 66356 65851 
#12 33585 32753 66047 75252 80235 97240 
#13 100628 52306 91536 92541 150930 129138 
#14 130534 144061 142213 149269 154589 163588 
#15 49801 75492 65629 84681 75637 103046 
#16 166859 189832 92688 110006 221335 223062 
 
 
Table 30 Mean and SEM values for JC-1 ratios of 16 MDD patients and controls fibroblast pairs 
 
mean SEM 
MMD N 1.401 0.008 
Control N 1.348 0.008 
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MDD DEX 1.449 0.006 
Control DEX 1.421 0.006 
MDD GAL 1.455 0.008 
Control GAL 1.421 0.009 
 
 
Table 31 Single red/green ratios for all 16 paired MDD and control cell lies 
Pair  MDD N Control N MDD DEX Control DEX MDD GAL Control GAL 
#1 1.31 1.30 1.44 1.36 1.35 1.19 
#2 1.43 1.39 1.42 1.54 1.49 1.58 
#3 1.31 1.40 1.32 1.25 1.24 1.23 
#4 1.26 1.18 1.44 1.30 1.32 1.35 
#5 1.33 1.40 1.37 1.42 1.39 1.32 
#6 1.18 1.00 1.31 1.30 1.33 1.39 
#7 1.43 1.39 1.43 1.40 1.41 1.35 
#8 1.50 1.43 1.38 1.30 1.62 1.47 
#9 1.41 1.46 1.36 1.41 1.31 1.18 
#10 1.57 1.41 1.54 1.56 1.49 1.60 
#11 1.50 1.27 1.36 1.39 1.44 1.50 
#12 1.41 1.55 1.61 1.40 1.55 1.66 
#13 1.55 1.55 1.53 1.56 1.52 1.70 
#14 1.50 1.50 1.53 1.48 1.56 1.42 
#15 1.23 1.33 1.57 1.52 1.51 1.45 
#16 1.54 1.41 1.55 1.51 1.43 1.63 
 
 
Table 32 Table 30 Mean and SEM values for Fura-2 ratios of 16 MDD patient and control pairs 
 
mean SEM 
MDD N 0.6767 0.0128 
Control N 0.6727 0.0088 
MDD DEX 0.6262 0.0054 
Control DEX 0.6204 0.0057 
MDD GAL 0.6262 0.0054 
Control DEX 0.6204 0.0057 
 
 
Table 33 Single ratio values for Fura-2 measurements in fbroblasts. 
Pair MDD N Control N MDD DEX Control DEX MDD GAL Control GAL 
#1 0.66 0.64 0.58 0.61 0.62 0.64 
#2 0.67 0.66 0.61 0.58 0.62 0.63 
#3 0.65 0.65 0.62 0.61 0.64 0.63 
#4 0.57 0.69 0.62 0.60 0.64 0.66 
#5 0.73 0.73 0.63 0.61 0.65 0.63 
#6 0.70 0.72 0.62 0.62 0.62 0.62 
#7 0.64 0.66 0.61 0.61 0.63 0.61 
#8 0.58 0.60 0.61 0.62 0.61 0.62 
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#9 0.63 0.69 0.64 0.64 0.66 0.64 
#10 0.72 0.72 0.62 0.62 0.64 0.68 
#11 0.68 0.66 0.67 0.65 0.64 0.61 
#12 0.72 0.71 0.64 0.61 0.62 0.65 
#13 0.72 0.65 0.61 0.62 0.65 0.64 
#14 0.71 0.64 0.62 0.63 0.65 0.66 
#15 0.72 0.67 0.63 0.66 0.69 0.68 
#16 0.72 0.68 0.66 0.61 0.67 0.63 
 
 
Table 34 Mean and SEM values of mtDNA copy numbers in fibroblasts. 
 
mean mtDNA 
copy number 
SEM 
MDD 654 28.04 
Control 636 31.68 
 
 
Table 35 mtDNA copy numbers for 16 MDD and control fibroblast cell lines. 
Pair mtDNA copy number 
 
MDD Control 
#1 623 582 
#2 634 618 
#3 760 711 
#4 577 584 
#5 606 540 
#6 728 501 
#7 564 819 
#8 486 738 
#9 829 609 
#10 767 375 
#11 882 893 
#12 578 668 
#13 655 745 
#14 512 545 
#15 587 589 
#16 681 652 
 
 
Table 36 Mean and SEM values of respiratory parameters of 9 MDD and control NPC pairs. 
 
Basal Respiration Maximal Respiration Spare Respiratory 
Capacity 
mean OCR SEM mean OCR SEM mean OCR SEM 
MDD N 88.49 3.42 114.94 5.55 27.40 1.44 
Control N 103.72 4.52 131.15 11.54 34.81 7.46 
MDD DEX 94.53 5.94 114.61 9.84 20.08 5.59 
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Control DEX 107.26 6.49 121.34 12.04 14.21 10.62 
 
 
non-mitochondrial 
Respiration 
Proton Leak ATP Prodction 
mean OCR SEM mean OCR SEM mean OCR SEM 
MDD N 25.54 1.20 16.63 0.79 72.55 2.70 
Control N 30.82 1.81 19.56 1.01 82.94 4.77 
MDD DEX 25.62 1.52 16.22 0.70 75.87 3.83 
Control DEX 28.00 1.40 21.02 2.96 85.27 4.64 
 
Table 37 OCR and ECAR values for 9 NPC MDD and control pairs. 
pair N DEX 
MDD CNTL MDD CNTL 
OCAR ECAR OCR ECAR OCR ECAR OCR ECAR 
#1 121.86 71.63 152.73 64.38 137.21 50.61 144.61 42.83 
#2 131.55 51.59 182.37 66.68 110.32 50.92 143.62 54.09 
#3 139.35 60.91 158.93 61.84 176.87 46.20 173.42 46.58 
#4 132.63 57.81 140.58 63.23 158.79 64.52 153.43 62.44 
#5 117.89 53.65 157.87 57.19 116.99 47.83 177.98 56.41 
#6 139.44 53.97 157.13 61.30 132.44 58.83 141.63 74.13 
#7 133.88 50.13 126.95 49.57 86.91 37.86 119.85 39.15 
#8 101.48 47.04 143.15 68.20 126.40 50.57 130.09 44.35 
#9 127.26 55.84 152.46 61.55 130.74 50.92 148.08 52.50 
 
Table 38  Mean and SEM values for JC-1 ratios of nine NPC MDD and control pairs. 
 
mean ratio SEM 
MDD N 1.696 0.065 
Control N 1.839 0.092 
MDD DEX 1.996 0.071 
Control DEX 2.079 0.115 
 
Table 39 Mean and SEM values for ATP measurements of 9 NPC MDD patients and control pairs 
 
mean SEM 
MDD N 341064 49780 
Control N 324275 47085 
MDD DEX 362357 65367 
Control DEX 369576 57303 
 
 
Table 40 Single RLU values of 9 MDD patient and control pairs of NPC lines 
Pair MDD N Control N MDD DEX Control DEX 
#1 210591 311489 127779 253116 
#2 532401 187508 496569 406236 
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#3 475031 381469 703305 748366 
#4 294678 335491 264349 257377 
#5 331633 595669 320698 280280 
#6 53072 224110 202532 168750 
#7 487705 474044 549283 499086 
#8 350901 169162 436798 352978 
#9 333564 239534 159903 359999 
 
 
Table 41 Single JC-ratios for 9 MDD and control NPC lines. 
pair MDD N Control N MDD DEX Control 
DEX 
#1 1.63 1.80 1.56 1.51 
#2 1.36 1.68 2.18 2.60 
#3 1.72 1.52 2.28 2.49 
#4 1.75 2.08 1.94 1.84 
#5 1.69 1.83 1.90 2.03 
#6 1.89 2.21 2.00 1.95 
#7 1.75 1.74 2.18 2.37 
#8 2.00 2.22 1.91 2.01 
#12 1.47 1.48 2.01 1.92 
 
 
Table 42 Mean and SEM values for Fura-2 ratios of 9 NPC MDD and control pairs 
 
mean ratio SEM 
MDD N 062 0.01 
Control N 0.60 0.01 
MDD DEX 0.62 0.01 
Control DEX 0.61 0.00 
 
 
 
Table 43 Single Fura-2 ratios for 9 MDD and control NPC cell lines. 
pair MDD Control MDD DEX Control DEX 
#1 0.60 0.62 0.62 0.61 
#2 0.64 0.60 0.62 0.59 
#3 0.62 0.60 0.63 0.59 
#4 0.59 0.60 0.58 0.60 
#5 0.62 0.60 0.62 0.62 
#6 0.63 0.62 0.60 0.63 
#7 0.65 0.57 0.66 0.60 
#8 0.62 0.56 0.62 0.62 
#9 0.62 0.62 0.63 0.60 
 
 
